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Abstract 
Innate  immune  signaling  pathways  initiate  host  defenses  against  viral 
pathogens.  Receptors  specific  for  viral  nucleic  acids  activate  these  pathways 
culminating in cell-to-cell communication and/or cell death. In mammals, this cell-
to-cell communication is achieved through the production of interferons and pro-
inflammatory  cytokines,  which  activate  antiviral  defenses  in  uninfected 
neighboring  cells  and  instruct  adaptive  immune  responses.  The  production  of 
these signaling molecules is essential for the defense against viral infection, but 
must  also  be  tightly  regulated  to  prevent  unnecessary  inflammation.  As  an 
antiviral  defense,  cell  death  is  also  an  effective  mechanism  to  limit  viral 
replication  and  spread  but  comes  with  the  cost  of  tissue  damage  and 
inflammation.  Therefore,  regulating  these  antiviral  responses  is  critical  for 
controlling the spread of infection as well as preventing unnecessary pathologies 
related  to  excessive  signaling.  Hundreds  of  genes  are  involved  in  controlling 
these  immune  responses  and  a  wide  variety  of  mechanisms  are  utilized  to 
regulate them. One mechanism to regulate gene function is the generation of 
protein variants through alternative translation. While polycistronic transcripts are 
a  common  feature  of  bacterial  and  viral  gene  expression,  the  process  of 
alternative  translation  as  a  means  to  regulate  gene  function  is  not  a  feature ! iv!
generally  attributed  to  mammalian  mRNA.  This  dissertation  describes  a  novel 
regulator of antiviral signaling that is generated through alternative translation. 
Expression of the transcript encoding the antiviral adaptor protein, MAVS, results 
in the production of two proteins: the full-length MAVS adaptor and a truncated 
variant, miniMAVS. Production of these proteins is in part regulated by cis-acting 
elements  that  control  translation  initiation.  Production  of  miniMAVS  regulates 
antiviral signaling by limiting interferon production induced by full-length MAVS, 
whereas  both  MAVS  variants  positively  regulate  cell  death.  To  identify  other 
examples of alternative translation in mammalian cells a genome-wide ribosomal 
profiling technique was used to generate a candidate list of antiviral truncation 
variants. This dissertation therefore demonstrates that protein variants generated 
through  alternative  translation  of  polycistronic  mRNAs  can  be  an  effective 
mechanism for immune regulation and may be more common than previously 
understood. 
   ! v!
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Chapter 1 
 
Introduction 
   ! 2!
Pattern Recognition by the Innate Immune System 
The innate immune system detects the presence of microbes and initiates 
mechanisms  to  eliminate  potentially  infectious  threats.  Microbial  detection  is 
achieved  through  germline  encoded  pattern  recognition  receptors  (PRR)  that 
survey both the extracellular and intracellular space for conserved determinants 
of microbial and viral origin
 1. These conserved determinants are recognized as 
indicators of microbial infection. The model of microbial pattern recognition was 
proposed by Charles Janeway Jr. and describes two feature of innate immunity: 
the ability to distinguish infectious non-self molecules from self-molecules and 
the ability to activate adaptive immune responses to the former
 2. In this model, 
the distinction between self and infectious non-self was predicted to rely on fixed 
receptor specificity for conserved molecular patterns common among pathogens. 
In addition, the activation of these receptors was predicted to initiate signaling 
events culminating in an effective immune response. Since Janeway made his 
prediction,  many  aspects  of  innate  immune  signaling  have  since  been 
characterized  and  fit  within  the  framework  of  his  original  model
  3.  Microbial 
ligands  ranging  from  structural  components  of  bacteria,  fungi,  and  viruses  to 
biosynthetic  molecules  such  as  nucleic  acids  activate  PRRs  and  induce  the 
innate immune responses that protect us from infectious threats. 
A major component of an innate immune response is transcriptional and 
generates the production of pro-inflammatory cytokines and interferons (IFN)
 4; 
these  chemical  messages  are  critical  for  initiating  innate  immune  defense 
mechanisms as well as initiating adaptive immune responses. The activation of ! 3!
PRRs  also  initiates  non-transcriptional  responses  such  as  the  induction  of 
phagocytosis,  cell  death,  autophagy,  and  cytokine  processing
  5-7.  These 
transcriptional  and  non-transcriptional  innate  immune  responses  are  linked  to 
PRR-mediated  microbial  detection  by  tightly  controlled  signal  transduction 
pathways
 1. The coordination of these signaling pathways orchestrates immune 
responses, which contain the spread of an initial infection as well as direct the 
appropriate adaptive response
 8. 
The majority of PRRs can be classified into one of five families based on 
protein domain homology. These five families consist of the Toll-like receptors 
(TLR),  C-type  lectin  receptors  (CLR),  nucleotide-binding  domain,  leucine-rich 
repeat containing (or Nod-like) receptors (NLR), the Rig-I-like receptors (RLR), 
and the AIM-2-like receptors (ALR)
 1. These families can be separated into two 
main  classes:  the  membrane-bound  receptors  and  the  unbound  intracellular 
receptors. The former class consists of the TLRs and CLRs, which are found at 
the  cell  surface  or  on  the  membranes  of  endocytic  compartments.  These 
receptors survey for the presence of microbial ligands in the extracellular space 
and within endocytic vesicles. The NLRs, RLRs, and ALRs form the later group 
being expressed within the cell cytoplasm where they survey for the presence of 
intracellular  pathogens.  While  the  PRRs  are  divergent  in  sequence,  ligand 
specificity, and cellular localization, together they coordinate to protect the host 
from  a  range  of  eukaryotic,  prokaryotic,  or  viral  pathogens.  However,  this 
dissertation  is  specifically  concerned  with  the  regulation  of  antiviral  innate ! 4!
immune responses; therefore it focuses on the characteristic responses to these 
infections and the subset of PRR pathways that regulate them. 
 
Antiviral Innate Immune Responses 
  The innate response to viral infection is initiated by a subset of PRRs and 
employs  generalized  mechanisms  that  broadly  respond  to  the  threat  of  viral 
infection
  9.  Unlike  an  adaptive  response,  the  innate  antiviral  response  is  not 
based on memory and is not tailored to a specific virus. It is classically defined by 
the production of type I interferon (IFN), which is a set of cytokines originally 
identified and named for their ability to “interfere” with viral replication
 10-12. The 
IFNs have been classified based on the receptor through which they bind and 
signal (type I, type II, and type III). Type I IFNs, which are the predominant form 
generated by PRR signaling, activate the IFN-alpha receptor and include IFN-
alpha and IFN-beta.  
Knockout  mice  with  deficiencies  in  PRR  signaling  demonstrate  the  link 
between PRR signaling and the production of type I IFN
 13-18. When challenged 
with  a  wide  range  of  viral  pathogens,  these  mice  are  highly  susceptible  to 
morbidity and mortality. In addition to the production of type I IFN, antiviral PRRs 
also induce the production of other pro-inflammatory cytokines
 9. Together these 
signaling  molecules  coordinate  several  aspects  of  the  antiviral  response.  For 
example, IFN signaling increases the expression of several antiviral PRRs. This 
change in expression increases the likelihood of viral detection as the infection 
spreads  to  uninfected  cells.  Furthermore,  IFNs  signal  in  an  autocrine  and ! 5!
paracrine fashion to induce the expression of interferon stimulated genes (ISG)
 
11. Many ISGs function as direct effectors against infection by interfering with viral 
mechanisms  of  genome  replication,  capsid  assembly,  or  shedding.  Therefore, 
the  expression  of  ISGs  at  the  site  of  infection  creates  an  antiviral  state  as  a 
countermeasure to prevent the spread of infection. Finally, the IFNs and pro-
inflammatory  cytokines  produced  during  an  antiviral  response  activate 
hematopoietic  immune  cells,  which  aid  in  pathogen  clearance  and  activate 
adaptive immune responses
 8, 11. In particular, type I IFN production is important 
for recruitment of NK and cytotoxic T cells to the site of infection as well as the 
proliferation and maintenance of NK cell and CD8
+ memory T cell populations
 19, 
20. 
The  antiviral  PRRs  that  induce  the  production  of  type  I  IFN  almost 
exclusively recognize nucleic acids
 21, 22. This may have evolved due to the fact 
that viruses have few invariant structural determinants and a high mutation rate. 
In this case nucleic acid detection serves as a suitable alternative to recognizing 
the structural features of a pathogen. While nucleic acids are a common feature 
among viral pathogens, they are also a biosynthetic component of the host cell 
biology. Therefore, a means for distinguishing nucleic acids as self or non-self is 
required to prevent autoimmune activation
 23. To this end, some of the receptors 
have  specificity  for  features  of  nucleic  acids  unique  to  the  genomes,  gene 
expression, or replication intermediates of viruses. This allows PRRs to reliably 
classify  non-self  viral  nucleic  acids  as  a  viral  infection  and  initiate  antiviral 
defenses. ! 6!
  There  is  a  large  and  growing  list  of  innate  immune  receptors  that 
recognize nucleic acids
 23. The best-characterized examples include members of 
the TLR and RLR families. The nucleic acid sensing TLRs survey endolysosomal 
compartments for the presence of both RNA and DNA molecules whereas the 
RLRs  survey  the  cytoplasmic  space  for  the  presence  of  viral  RNA.  Several 
receptors responsible for detecting cytosolic DNA have also been described; with 
the  enzyme  cyclic  GMP-AMP  synthase  (cGAS)  being  the  only  DNA  sensor 
whose function is supported by genetic evidence in mice and humans
 24-26. cGAS 
and perhaps other DNA sensors signal via the ER-localized protein STING which 
activates IFN production in response to cytosolic DNA
 27-29. While each of the 
nucleic  acid-sensing  PRRs  have  a  unique  role  in  the  contribution  to  antiviral 
defense,  this  dissertation  will  be  focusing  specifically  on  the  regulation  of  the 
RLR signaling pathway.  
 
The RIG-I-like Receptor Family 
  A family of three helicase domain-containing proteins make up the RLRs 
involved  in  cytosolic  RNA  detection
  30.  The  founding  member,  retinoic  acid 
inducible gene I (RIG-I), and melanoma differentiation-associated gene 5 (MDA5) 
have  been  most  thoroughly  characterized.  Nucleic  acid  ligand  recognition  by 
RIG-I  requires  a  5’  triphosphate,  present  on  many  viral  genomes,  as  well  as 
secondary structure such as a panhandle caused by base pairing
 31-34. There is 
also evidence for some RIG-I sequence specificity based on recognition of the 
poly-U/UC region within the HCV genome
 35, 36. The ligand specificity for MDA5 is ! 7!
less well understood, but this receptor will respond to aggregated forms of long 
double stranded RNA
 37-39. These features such as a 5’ triphosphate or double 
strandedness are not common among host RNAs and allow for the distinction 
between viral and host RNA within the cytosol. 
Both  RIG-I  and  MDA5  share  a  similar  domain  structure  and  some 
regulatory  features.  These  receptors  contain  two  caspase  activation  and 
recruitment (CARD) domains at their N-terminus, a centrally located DExD/H box 
helicase domain, and a C-terminal domain (CTD)
 40. The helicase and CTD are 
involved in viral RNA binding, whereas the tandem N-terminal CARD domains 
are  required  for  the  interaction  with  the  downstream  mitochondrial  antiviral 
signaling  adaptor  (MAVS).  At  steady  state  the  receptors  are  maintained  in  a 
closed conformation with the CARDs bound to the helicase domain to prevent 
aberrant signaling. RNA binding results in conformational changes that make the 
tandem  CARDS  accessible.  The  CARDs  are  then  post-translational  modified 
and/or interact with the adaptor MAVS
 41.  
The  post-translational  modifications  regulating  the  activity  of  the  RLRs 
include  the  addition  of  K63-linked  ubiquitin  chains  and  the  removal  of  a 
phosphate  group
  42.  The  E3  ubiquitin  ligases  Tripartite  motif-containing  25 
(TRIM25) and Riplet (also known as RNF135) both modify RIG-I with K63-linked 
ubiquitin chains and are required for RIG-I activation
 43-45. Trim25 produces K63-
linked ubiquitin chains that interact with Lys 172 within CARD2 whereas Riplet 
modifies a region within the C-terminus of RIG-I
 43, 44. While K63 ubiquitin chains 
are required for signaling, RIG-I in conjunction with unanchored K63 ubiquitin ! 8!
chains  induce  MAVS  activation  in  vitro  indicating  that  the  covalent  linkage  to 
RIG-I  is  not  a  requirement
  46.  The  presence  of  K63-linked  chains  supports 
structural  stabilization  of  a  CARD  tetramer  which  can  activate  the  function  of 
MAVS
 47. At resting state the RLRs each have phosphate group modifications 
that must be removed for the receptor to be activated. The protein phosphatases 
1 alpha and 1 gamma are involved in this step of RLR activation. In addition to 
these post-translational modifications involved in regulating RLR activity, RIG-I 
and  MDA5  form  filamentous  structures  that  are  capable  of  inducing  MAVS 
activation
  48,  49.  However,  ubiquitin  modification  and  filament  formation  are 
individually sufficient for RIG-I to activate MAVS, but these two mechanisms may 
function  together  synergistically
  47.  Taken  together,  we  can  appreciate  that  a 
number of regulatory steps are involved in controlling RLR activation and the 
induction of antiviral immune responses. 
The  role  of  the  third  RLR  family  member,  Laboratory  of  Genetics  and 
Physiology  2  (LGP2),  in  antiviral  signaling  has  been  somewhat  controversial. 
Similar to RIG-I and MDA5, LGP2 contains a DExD/H box helicase domain and a 
CTD
  30.  As  this  receptor  lacks  the  N-terminal  CARD  domain  required  for 
interacting with the downstream adaptor MAVS, it was initially hypothesized and 
demonstrated to function as a negative regulator of antiviral signaling
 30, 50. Since 
the generation of LGP2 knockout mice however, reports indicate a positive role 
for LGP2 in RIG and MDA5 mediated antiviral signaling
 51. Some of the confusion 
behind  LGP2  function  may  have  been  due  to  the  use  of  non-physiological 
conditions  including  transient  gene  expression  and  activation  using  synthetic ! 9!
ligands.  Specifically,  LGP2  is  dispensable  for  the  IFN  response  to  synthetic 
ligands but is required for the response to infection from a number of viruses. 
While the role of LGP2 in antiviral signaling requires further clarification, it is not 
likely  that  this  receptor  exerts  an  effect  through  direct  interaction  with  the 
downstream adaptor MAVS because it lacks a CARD domain. 
 
The Antiviral Signaling Adaptor MAVS 
  In 2005, four groups individually identified an antiviral gene that encodes 
the adaptor protein MAVS (also referred to as IPS-1, Cardif, and VISA)
 52-55. As 
mentioned above, both RIG-I and MDA5 require the signaling adaptor MAVS for 
IFN  production  making  it  a  critical  component  of  antiviral  defense.  The 
importance  of  MAVS  in  antiviral  defense  has  been  demonstrated  with  the 
generation of MAVS deficient mice that are highly susceptible to infection from a 
number of RNA viruses
 15, 16. The domain organization of MAVS consists of a 
single N-terminal CARD domain, a proline-rich region (PRR), and a C-terminal 
transmembrane (TM) domain (Figure 1.1).  
   ! 10!
 
 
 
 
 
 
 
In addition to providing a platform for CARD-mediated RLR interactions, 
the CARD domain of MAVS is required for self-activation and IFN production. 
Upon activation MAVS undergoes polymerization creating prion-like aggregates 
that induce signal transduction
 56. These aggregates share some features with 
classically defined prions and require the CARD domain for propagation. MAVS 
aggregation activates a set of cytosolic kinases (TBK1, IKK) and transcription 
factors  (IRF3,  NF-κB)  culminating  in  the  expression  of  type  I  IFNs,  pro-
inflammatory cytokines, and ISGs (Figure 1.2)
 57.  
Figure 1.1 The domain structure of MAVS 
The N-terminal  caspase activation and recruitment domain  (CARD) 
and  a  C-terminal  transmebrane  (TM)  domain  are  required  for  the 
MAVS  dependent  IFN  response.  Some  reports  indicate  that  the 
proline-rich  region  (PRR)  is  required  for  some  protein-protein 
interactions. ! 11!
 
 
A  defining  feature  of  MAVS  function  and  regulation  is  dictated  by  its 
subcellular localization. When MAVS was initially identified, Seth and colleagues 
noted that the C-terminal transmembrane domain (Figure 1.1) resembled that of 
other tail-anchored mitochondrial proteins
 52. The authors demonstrated that the 
adaptor  co-localized  and  signaled  from  mitochondria  and  justly  named  the 
Figure 1.2 MAVS dependent antiviral responses 
Viral RNAs within the cytosol activate the innate receptors, RIG-I and 
MDA5, which signal through MAVS. This antiviral signaling adaptor is 
required  for  the  activation  of  downstream  transcription  factors  that 
orchestrate  the  production  of  IFN,  pro-inflammatory  cytokines,  and 
ISGs.  In  addition,  MAVS  induces  cell  death  in an  IFN-independent 
manner. ! 12!
adaptor  mitochondrial  antiviral  signaling  protein.  In  addition  to  mitochondria, 
MAVS  is  also  localized  on  and  signals  from  peroxisomal  and  mitochondrial 
associated membranes (MAMS) of the endoplasmic reticulum (ER)
 58, 59. During 
viral infection, RIG-I and TRIM25 are delivered to these sites of signaling by the 
mitochondrial chaperone protein 14-3-3ε
 60. MAVS variants that either lack the 
transmembrane domain or are genetically targeted to other subcellular locations 
have impaired function indicating a localization requirement for the adaptor
 52, 58. 
Even though these inactive variants retain the regions necessary for interacting 
with downstream signaling proteins, they are incapable of inducing an interferon 
response.  
While MAVS requires proper membrane localization to one of these sites 
of signaling, it is important to note that the MAVS-induced signaling outcome can 
differ  from  these  sites.  Specifically,  MAVS  signaling  from  mitochondrial  and 
peroxisomal membranes initiates distinct transcriptional profiles
 58. Signaling from 
the mitochondrial membrane induces the expression of type I IFN, which results 
in the subsequent expression of ISGs. In contrast, peroxisomal signaling induces 
the expression of ISGs independently of type I IFN expression. The mechanisms 
at work that regulate organelle specific signaling and the biological advantage 
this system offers have yet to be determined. It is tempting to speculate that 
factors unique to each organelle are responsible for dictating organelle specific 
signaling. An interesting feature of mitochondrial and peroxisomal biology is that 
these organelles interact through MAMs, which form a specialized subdomain of ! 13!
the  ER.  This  synaptic  interface  between  mitochondria  and  peroxisomes 
coordinates an effective MAVS-dependent response to HCV infection
 59. 
 
Signaling Downstream of MAVS 
The  RLR/MAVS  signaling  pathway  is  extensively  regulated  by  ubiquitin 
modifications,  and  similar  to  the  RIG-I/ubiquitin  signaling  upstream  of  MAVS, 
downstream  signaling  also  requires  the  ubiquitin  system.  The  TNF  receptor 
associated  family  (TRAF)  proteins  are  a  set  of  E3  ubiquitin  ligases  that  are 
involved  in  the  regulation  of  TNF  receptor  signaling  as  well  as  other  innate 
immune signaling pathways
 61. The enzymatic activity of the TRAFs are involved 
in attaching ubiquitin to a targeted substrate, and several members of the TRAF 
family  are  involved  in  IFN  and  cytokine  production
  62.  When  MAVS  was  first 
identified, it was noted to contain several TRAF binding domains that interact 
with TRAF2 and TRAF6
 52, 55. Other TRAF family members, TRAF3 and TRAF5, 
also interact with MAVS
 63-65. As noted above, the aggregation of MAVS prion-
like polymers is critical for the induction of downstream signaling. Interestingly, 
these  aggregates  are  capable  of  specifically  recruiting  TRAF2  and  TRAF6  in 
response  to  viral  infection
  56.  Mutating  the  TRAF  binding  sites  results  in  the 
formation of MAVS polymers that are incapable of recruiting TRAF proteins or 
inducing  the  production  of  IFN
  57.  This  demonstrates  that  the  TRAF  signaling 
function is downstream of the aggregation of MAVS polymers. The number of 
TRAFs  found  to  associate  with  MAVS  and  the  fact  that  several  TRAFs  are 
partially required for signaling is indicative of functional redundancy
 52, 55. This ! 14!
redundancy for TRAF2, TRAF5, and TRAF6 demonstrates a requirement for the 
E3  ligase  activity  of  these  TRAF  proteins
  57  and  indicates  that  a  downstream 
signaling  molecule  may  subsequently  sense  ubiquitin  modifications  made  by 
them. 
  The NFκB essential modulator (NEMO) is a ubiquitin sensor that regulates 
the activity of the kinases IKK and TBK1, which regulate the transcription factors 
NFκB and IRF3 respectively
 62, 66. The ubiquitin binding domains of NEMO are 
required for activation of IRF3 in response to RNA viral infection
 67. Furthermore, 
NEMO forms a complex with MAVS, TRAFs, and TBK1 as part of the response 
to RNA viruses
 57, 68. Therefore, the TRAF ubiquitin ligases are required for the 
formation of a signaling complex containing NEMO and MAVS polymers. Other 
signaling  molecules  may  also  be  present  in  this  complex,  which  ultimately 
activates the cytosolic kinases IKK and TBK1 (Figure 1.2). The activity of the IKK 
complex  and  TBK1  phosphorylates  the  inhibitor  of  NFκB  (IκBα)  and  IRF3 
respectively
 69, 70. IκBα phosphorylation indirectly activates the transcription factor 
NFκB  by  releasing  it  for  translocation  to  the  nucleus.  Conversely, 
phosphorylation  directly  activates  the  transcription  factor  IRF3,  which  forms 
homodimers  prior  to  nuclear  translocation  and  transcriptional  regulation
  71-74. 
Together  these  transcription  factors  function  to  coordinate  the  expression  of 
antiviral genes.  
   ! 15!
IFN Independent MAVS Mediated Cell Death 
While the majority of MAVS research has focused on IFN production, it is 
worth noting that the RLR pathway can also limit viral replication by initiating cell 
death (Figure 1.2)
 75-79. Similar to IFN production, control of this cell biological 
process is MAVS dependent and also requires correct localization of the adaptor
 
76. However, the induction of cell death is independent of MAVS induced IFN 
signaling
 80, 81. The signaling events downstream of MAVS controlling cell death 
have yet to be fully characterized, but a few reports have identified a subset of 
genes that are involved in the process. For example, caspase inhibition limits 
MAVS induced cell death indicating that caspase activation is a component of 
this process. A few distinct forms of cell death such as apoptosis or necrosis can 
be  induced  by  caspase  activation,  yet  the  specific  form  induced  by  MAVS 
remains to be defined
 82. Several proteins with known cell death functions can 
interact  with  MAVS  and  contribute  to  the  regulation  of  MAVS-mediated  cell 
death. Some of these include, VDAC1, TRADD, and caspase 8
 81, 83, 84. TRADD 
has  been  shown  to  interact  with  MAVS  and  recruit  the  proapoptotic  proteins 
FADD and RIP1
 53, 84. In addition, MAVS mediated SeV-induced death requires 
the kinases c-Jun N-terminal kinase 2 (JNK2) and MAPK kinase 7 (MKK7)
 85. 
While much remains to be characterized in the activation of cell death by MAVS, 
it  is  interesting  to  note  that  cell  death  does  not  rely  on  IFN  signaling  as 
demonstrated by cell death competent IFN incompetent MAVS constructs
 76, 86. 
In  addition  to  not  requiring  the  IFN  inducing  capacity  of  MAVS,  it  is 
interesting that cell death can be induced independently of the RLR receptors. ! 16!
For  example,  SeV-induced  death  occurs  independently  of  RIG-I
  85,  and  VSV-
induced  cell  death  does  not  require  the  CARD  domain  of  MAVS
  81.  If  MAVS 
mediated cell death does not require its CARD domain or the upstream RLR 
receptors, how does this critical adaptor receive a signal indicating infection? Do 
other receptors exist that induce MAVS-mediated cell death? Future studies will 
be needed to address these questions and characterize how MAVS regulates the 
process of virus induced cell death.  
 
MAVS Regulation 
The  antiviral  IFN  and  cell  death  responses  described  above  must  be 
tightly regulated. The inability to control these responses can make a host more 
susceptible to infection if the levels of IFN production or cell death are insufficient
 
15, 16. Conversely, excessive antiviral responses can be detrimental to the host 
and incur pathology at the cost of inflammation and cell damage
 87. Most of the 
regulators that directly target MAVS have been characterized in the context of 
IFN production, and are discussed below. While MAVS induced cell death and 
IFN  responses  are  independent  of  each  other,  it  is  possible  that  some  these 
regulators affect both responses.  
The self-aggregation of MAVS might be classified as the first regulator of 
MAVS  function,  however  there  are  a  number  of  mechanisms  at  work  that 
additionally  regulate  the  function  of  MAVS.  Some  of  these  regulatory 
mechanisms include protein-protein interactions, post-translational modifications, 
mitochondrial  dynamics,  autophagy,  as  well  as  protease  cleavage.  Several ! 17!
regulators can either inhibit or potentiate MAVS signaling by direct protein-protein 
interaction. NLRX1, UBXN1, and TSPAN6 each physically interact with MAVS 
and negatively regulate the production of IFN
 88-91. These interactions may inhibit 
IFN production by preventing the binding of signaling or interfering with MAVS 
polymerization. The role of NLRX1 in MAVS dependent signaling has been a 
matter of a debate with some groups claiming that it does not function as an 
inhibitor of IFN production
 92, 93. However, as discussed below, a more recent 
publication  proposes  that  NLRX1  may  regulate  autophagy  in  addition  to  IFN 
production
 94. Positive regulators of MAVS dependent signaling, such as Tom70 
and IFIT3, also interact with the adaptor
 95, 96. In both cases these regulators 
facilitate  MAVS  interaction  with  the  downstream  signaling  kinase  TBK1  to 
promote  IRF3  activation.  While  protein-protein  interaction  is  one  proposed 
mechanism for controlling MAVS signaling, several other proteins interact with 
MAVS and impart their regulatory effects through modification of the adaptor. 
Both  ubiquitination  and  phosphorylation  are  signal-induced  post-
translational modifications made to MAVS that regulate its function. While K63-
linked polyubiquitin chains are involved in RIG-I mediated activation of MAVS, 
covalent ubiquitin modification of MAVS is primarily a form of negative regulation. 
A  number  of  genes  participate  in  this  negative  regulation  including:  PSMA7, 
PCBP2/AIP4, PCBP1/AIP4, Ndifp1/Smurf1, and Smurf2
 97-101. With the exception 
of  PSMA7  (due  to  a  lack  of  experimental  evidence)
  97,  these  regulators 
specifically  attach  K48-linked  ubiquitin  chains  to  MAVS.  This  is  somewhat 
expected because K48-linked ubiquitin modification is commonly used to target ! 18!
proteins  for  proteolysis,  whereas  K63-linked  ubiquitin  coordinates  other 
processes  such  as  the  RIG-I  mediated  activation  of  MAVS  described  earlier. 
Interestingly, there is one example of K63-linked ubiquitin modification of MAVS. 
This modification at lysine 500 mediates recruitment of IKKε to the adaptor and 
negatively  regulates  NF-κB  activation  and  IFN  production
  102.  This  is  the  only 
reported  form  of  ubiquitin  mediated  MAVS  regulation  that  is  independent  of 
proteasomal degradation. The E3 ubiquitin ligase responsible for this K63-linked 
modification  at  lysine  500  remains  to  be  identified.  In  addition  to  ubiquitin 
modification,  phosphorylation  of  MAVS  can  affect  its  function  following  viral 
infection.  Extensive  tyrosine  phosphorylation  of  MAVS  occurs  with  specific 
phosphorylation at tyrosine 9 required for signaling and IFN production
 103. The 
tyrosine kinase c-Abl targets MAVS and positively regulates IFN production, but it 
remains  to  be  determined  whether  it  is  the  kinase  responsible  for  tyrosine  9 
modification
 104. Together, these post-translational modifications regulate MAVS 
function as part of a coordinated antiviral response. 
As mentioned above MAVS is localized to a set of organelles that interact 
with each other and are highly dynamic. Changes in the mitochondrial network 
occur  following  activation  of  the  RLR  pathway,  and  perhaps  not  surprisingly 
mitochondrial  dynamics  appear  to  regulate  MAVS  signaling
  105.  Mitochondrial 
fusion is one such event that plays a role in this form of regulation. Cells deficient 
in  regulators  of  mitochondrial  fusion,  Mitofusin  1  or  Mitofusin  2,  display 
impairments  in  mitochondrial  fusion  and  IFN  signaling  in  response  to  viral 
infection
 106, 107. This indicates that mitochondrial fusion events regulate the RLR ! 19!
signaling  pathway.  One  possible  mechanism  of  this  regulation  could  be  that 
mitochondrial  fusion  contributes  to  the  aggregation  of  MAVS  for  its 
polymerization.  While  several  reports  provide  evidence  in  agreement  that 
mitochondrial fusion positively contributes to MAVS activation, there is one report 
that  Mitofusin  2  functions  alternatively  to  inhibit  MAVS  through  protein-protein 
interaction. In support of this hypothesis, increased IFN signaling was observed 
in Mitofusin 2 knockout cells
 108. Thus Mitofusin 2 may function as positive or 
negative  regulator  of  IFN  production  through  mitochondrial  fusion  or  direct 
interactions  respectively.  Regardless,  mitochondrial  dynamics  have  some 
regulatory function in MAVS signaling, but it remains to be determined whether 
regulators  of  peroxisome  and  ER/MAM  physiology  also  affect  the  signaling 
outcomes of the RLR pathway. 
In  addition  to  altered  mitochondrial  dynamics,  viral  infection  is  also 
associated  with  the  induction  of  autophagy.  This  catabolic  process  of  cell 
physiology  is  utilized  for  the  maintenance  of  cellular  health.  It  degrades 
intracellular components at baseline levels, but can be induced in response to 
cellular  stresses  such  as  organelle  dysfunction  and  viral  infection.  While 
autophagy has been implicated in the immune response to viral infection as a 
form  of  targeted  pathogen  elimination
  109,  it  is  not  clear  that  this  process  is 
regulated by RLR signaling. Rather, autophagy may negatively regulate MAVS 
dependent IFN responses by targeting mitochondria resulting in higher rates of 
viral replication
 110. Mediators of this process include Atg5, Atg12, NLRX1, TUFM, 
and COX5B
 94, 111, 112. Interfering with these regulators inhibits the formation of ! 20!
autophagosomes resulting in higher levels of IFN production and decreased viral 
replication.  The  question  of  how  autophagy  functions  to  negatively  regulate 
MAVS signaling requires further characterization. Some proposed mechanisms 
include  the  removal  of  damaged  mitochondria,  the  degradation  of  aggregated 
MAVS complexes, and the reduction in reactive oxygen species. Identifying the 
cellular  biological  events  that  control  the  MAVS-autophagy  axis  will  provide 
further insight into the regulation of this innate signaling pathway. 
As a way to subvert host-mediated antiviral measures, viruses have also 
evolved their own tactics of regulating the function of MAVS. Targeting MAVS for 
proteolytic cleavage is an immune evasion strategy employed by many viruses. 
This connection was made with Hepatitis C Virus (HCV) in one of the original 
papers that identified MAVS
 54. The HCV encoded protease NS3/4A blocks IFN 
production  during  viral  infection  by  cleaving  MAVS.  These  authors  also 
generated a protease resistant variant of MAVS with a point mutation altering the 
cysteine at amino acid 508 of human MAVS to an alanine
 54. Several other viral 
proteases also cleave MAVS and as a result decrease IFN production during 
infection.  Some  of  the  viruses  encoding  these  proteases  include  GB  virus  B, 
Hepatitis  A  Virus,  Human  Rhinovirus  1a,  Coxsackievirus  B3  (CVB3),  and 
Enterovirus  71  (EV71) 
  113-117.  The  3ABC  protease  precursor  encoded  by 
Hepatitis A virus targets the cysteine protease 3C
pro to mitochondria, which can 
cleave  MAVS  near  its  C-terminus  as  demonstrated  by  a  Q428A  protease 
resistant mutant
 114. Similar to NS3/4A, this MAVS proteolysis disrupts interferon 
signaling  and  antiviral  defense.  Rather  than  targeting  the  C-terminus  for ! 21!
cleavage, both CVB3 and EV71 encoded cysteine proteases target the proline-
rich region of MAVS
 116, 117. A Q148A mutation in MAVS disrupts cleavage by 
3C
pro of Coxsackievirus B3, whereas the Enterovirus 71-encoded protease 2A
pro 
may have multiple targets and requires glycine to alanine mutations at residues 
209,  251,  and  265  of  MAVS  to  completely  block  proteolysis.  Neither  the 
respective  N-terminal  or  C-terminal  cleavage  products  generated  by  these 
proteases are capable of inducing an IFN signaling response. While the MAVS 
C-terminal  fragments  retained  mitochondrial  localization,  the  loss  of  the  N-
terminal CARD domain was sufficient to disrupt IFN signaling function. Therefore 
a large number of virus-employed evasion strategies have evolved to manipulate 
MAVS signaling. However, many of these virus-encoded proteases can serve 
multiple  functions  by  targeting  several  host-encoded  proteins.  For  example 
NS3/4A of HCV and 3C
pro of CVB3 can also cleave TRIF to interfere with TLR 
driven antiviral responses
 116, 118. Therefore, it can be difficult to determine the 
relative importance of each target during viral infection. Further characterization 
of  these  viral  immune  evasion  tactics  will  not  only  provide  insight  into  MAVS 
regulation but may also highlight potential antiviral therapeutic targets. 
In conclusion, the function of MAVS is dynamically regulated by a number 
of  different  mechanisms.  The  strategies  employed  in  MAVS  regulation  range 
from direct protein interaction to regulated cell processes such as mitochondrial 
fusion.  However,  in  addition  to  host-encoded  regulation,  viruses  can  also 
regulate the function of this antiviral adaptor. In future studies it will be important 
to  dissect  how  these  regulators  function  in  context  with  each  other  and  to ! 22!
specifically  understand  how  these  regulators  function  in  the  context  of  MAVS 
polymerization. 
 
Regulation of Innate Immune Responses Through Protein Diversification 
  The  number  of  MAVS  regulators  described  in  the  previous  section 
demonstrates not only the extent but also the range of mechanisms available for 
controlling antiviral gene function. However, one regulatory mechanism yet to be 
described is the ability to generate protein diversity from within a single genetic 
locus.  For  example,  one  gene  can  generate  a  diverse  set  of  protein  variants 
through  the  mechanism  of  alternative  splicing.  This  is  a  form  of  mRNA 
processing can dictate gene function by removing or altering the protein domains 
encoded on a transcript. In addition to generating a diverse set of transcripts from 
a single gene, a diverse set of proteins can be produced from a single transcript 
through alternative translation. These two processes offer an effective way to 
alter protein activity by swapping in and out domains to diversify the function of a 
single genetic locus. 
  The first form of protein diversification, alternative splicing, is a form of 
mRNA  processing  that  is  restricted  to  eukaryotic  organisms.  There  are  many 
genes that encode alternative splice variants including the gene encoding RIG-I
 
119. Compared to the full-length protein, the RIG-I splice variant (RIG-I sv) lacks a 
short region within the first CARD domain corresponding to amino acids 36-80 of 
RIG-I. This region is required for TRIM25 binding and without it the RIG-I sv is 
not  capable  of  activating  the  pathway.  Since  the  expression  of  RIG-I  sv  is ! 23!
induced following viral infection and can inhibit RIG-I-mediated IFN production, it 
appears to resolve antiviral signaling via its dominant negative function. Many 
other  innate  immune  genes  encode  splice  variants  that  regulate  signaling 
including the genes that encode MAVS, MyD88, and TRAM
 120-122. 
  Alternative translation is a second process of generating protein diversity, 
which occurs when protein synthesis is initiated from more than one start codon 
on a single transcript. In contrast to alternative splicing, which is exclusive to 
eukaryotic  organisms,  alternative  translation  is  a  feature  more  common  to 
bacterial  and  viral  transcripts
  123.  In  fact,  the  scarcity  of  alternative  translation 
examples described in higher organisms has led to the consensus that it is not a 
generalized mechanism for creating protein diversity in mammalian cells
 124. The 
few examples that do exist have instead been considered exceptions to the rules 
of gene regulation in mammals
 125-132. However, genome-wide ribosomal profiling 
studies now suggest that polycistronic mRNAs are more prevalent in eukaryotes 
than previously appreciated
 133. Ribosomal profiling is a technique that identifies 
the footprint, or position, of a ribosome on a transcript by sequencing mRNA 
associated  with  it
  134.  In  conjunction  with  the  drug  harringtonine,  ribosomal 
profiling  can  be  used  to  identify  translation  initiation  sites  from  endogenous 
mRNA transcripts
 135, 136. Harringtonine is a natural compound that inhibits the 
elongation step of translation and stalls ribosomes at sites of initiation. Ribosomal 
profiling studies have revealed that thousands of transcripts may contain more 
than one site of translation initiation. Future studies are required to determine ! 24!
whether translation occurs from these newly identified start sites and whether the 
products of this synthesis are functional.  
  All  of  the  known  examples  of  protein  diversification  that  regulate  the 
MAVS antiviral innate signaling pathways fit within the first class of alternative 
splicing.  To  date,  no  example  has  been  described  within  the  context  of 
alternative translation. This dissertation describes the first example of an antiviral 
innate  immune  signaling  variant  generated  by  alternative  translation.  The 
transcript  encoding  the  antiviral  signaling  adaptor  MAVS  is  bicistronic  and 
encodes  FL  MAVS  and  a  truncated  variant,  miniMAVS,  through  alternative 
translation.  Therefore,  the  regulation  of  antiviral  signaling  depends  on  the 
translation  of  a  variant  from  a  downstream  start  codon  within  the  MAVS 
transcript. However, certain regulatory mechanisms must be in place to allow for 
translation events at downstream start codons.  
 
Cis-encoded  Regulatory  Mechanisms  of  Translation  Initiation  at 
Downstream Start Codons  
  At the onset of translation the 40s ribosomal subunit binds to the 5’ cap of 
an mRNA transcript and begins scanning, or processing in a 3’ direction until it 
encounters an optimal start codon
 137. During initiation at this start codon, the 60s 
ribosomal  subunit  is  recruited  to  the  complex  prior  to  the  elongation  step  of 
protein synthesis. Based on this model of ribosomal scanning, it is not intuitively 
clear how the translation machinery reaches downstream start codons to initiate 
protein synthesis. Leaky ribosomal scanning is one of the mechanisms described ! 25!
to  regulate  translation  at  these  downstream  start  codons
  138.  In  this  process, 
ribosomes “leak” or scan past start codons that are suboptimal. This insufficiency 
in ribosome initiation is dictated by the nucleotide sequence directly surrounding 
a start codon and is referred to as the translational context at a start site
 139. Start 
sites with a strong translational context are optimal for protein synthesis, whereas 
weak  translational  start  sites  have  suboptimal  conditions  for  initiation.  Marilyn 
Kozak  made  this  distinction  and  characterized  the  consensus  sequence  for 
optimal  translation  initiation  on  eukaryotic  mRNA
  140.  Therefore,  a  weak 
translation  context  at  upstream  start  codons  may  allow  for  leaky  ribosomal 
scanning and the alternative translation from downstream start codons. 
  A  second  mechanism  that  allows  for  translation  from  downstream  start 
sites is through the use of internal ribosomal entry site (IRES) elements. These 
cis-encoded sequences within the RNA can directly recruit ribosomal subunits 
independently  of  a  5’  cap
  141.  It  has  been  hypothesized  that  ribosomes  are 
recruited  to  secondary  or  tertiary  structures  formed  by  these  nucleotide 
sequences.  While  RNA  transcripts  encoded  by  viruses  commonly  use  IRES 
elements, the existence of eukaryotic encoded IRES elements is controversial 
because they are not as common and are comparatively less efficient
 142. 
  In addition to leaky ribosomal scanning and IRES elements, translation 
initiation at small upstream open reading frames (uORFs) within the UTR can 
regulate translation at downstream start codons
 143. A number of uORF related 
factors  can  contribute  to  downstream  start  site  regulation.  For  instance,  the 
translational  context  at  uORFs  may  regulate  whether  ribosomes  continue ! 26!
scanning down to the canonical ORF of a transcript. Furthermore, the number of 
uORFs within the UTR as well as the distance between a uORF termination site 
and a canonical ORF start site can affect the expression of the canonical ORF. A 
particularly interesting model for regulating downstream start sites has also been 
proposed for uORFs that overlap other translational start sites
 125, 143. Translation 
of the overlapping uORF offers a mechanism for a ribosome to pass a canonical 
ORF start site (Figure 1.3). Once a translating ribosome terminates translation of 
the overlapping uORF, it may resume scanning and then re-initiate translation at 
the start codon of a downstream ORF (Figure 1.3)
 144. One parameter controlling 
the efficiency of re-initiation is the intercistronic length between termination and a 
second start site. 
 
 
Figure 1.3  A  mechanistic  model for  how  an  overlapping  uORF 
may regulate translation of downstream ORFs 
Shaded  boxes  highlight  the  open  reading  frames  present  on  this 
cartoon  depiction  of  an  mRNA  transcript.  The  arrows  indicate  the 
translational start site locations on the transcript. Ribosomes that are 
translating the uORF can pass the start site for the canonical ORF 
and re-initiate at the downstream ORF start site.  ! 27!
  Therefore, cis-encoded regulatory elements within mRNA transcripts, such 
as the translational context at a start codon, IRES elements, and uORFs, may 
help dictate start codon usage. In addition, translation initiation factors and other 
trans-regulatory  elements  can  control  gene  expression  by  regulating how  and 
when protein synthesis is initiated from different start sites. Now that ribosomal 
profiling  has  indicated  a  higher  incidence  of  polycistronic  messages  than 
previously appreciated, it will be important to characterize the variants generated 
in  addition  to  understanding  the  regulatory  mechanisms  that  control  their 
translation. 
   ! 28!
Dissertation Objective 
Since Charles Janeway’s hypothesis that innate immune responses were 
classified  and  initiated  by  a  set  of  receptors  with  fixed  specificity,  our 
understanding  of  innate  immune  signal  regulation  has  grown  exponentially
  1. 
Hundreds  of  genes  and  regulatory  mechanisms  participate  in  the  controlled 
response  to  microbial  infection.  However,  many  gaps  still  exist  in  our 
understanding of how these pathways are controlled. Recently ribosomal profiling 
studies have discovered that a significant percentage of mammalian transcripts 
may have more than one functional site of translation initiation
 133. The products 
generated from these alternative translation start sites may play an important role 
in  many  biological  processes.  This  dissertation  describes  an  example  of  an 
antiviral  innate  signaling  variant  generated  from  a  bicistronic  mRNA.  This 
highlights the use of alternative translation as a means of gene regulation that 
may be more common than previously appreciated. Chapter two demonstrates 
that the transcript encoding MAVS is bicistronic encoding the full-length MAVS 
protein  and  truncated  variant  miniMAVS.  Then  chapter  three  investigates  the 
regulatory function of miniMAVS in the context of antiviral IFN production and cell 
death.  The  results  of  a  genome-wide  ribosomal  profiling  study  conducted  to 
identify other regulators of innate immunity generated by alternative translation 
are described in chapter four. Finally, chapter five provides a general discussion 
of the results presented in this dissertation, their implications, and directions for 
future research. 
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Chapter 2 
 
The Bicistronic MAVS Transcript Encodes a Truncated Variant 
The substance of this chapter was previously published. 
 
Brubaker, S.W., Gauthier, A.E., Mills, E.W., Ingolia, N.T. & Kagan, J.C. 2014, 
"A bicistronic MAVS transcript highlights a class of truncated variants in antiviral 
immunity", Cell, vol. 156, no. 4, pp. 800-811. 
 
 
 
 
 
 
 
Contributions: N.T. Ingolia performed and analyzed the ribosomal profiling 
described in Figure 2.4. All other experiments were designed and executed by 
S.W. Brubaker. 
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INTRODUCTION 
Chapter one discusses the innate immune signal transduction pathways 
that induce immune responses to microbial infection. These responses and the 
inflammation associated with them control the spread of infection, but they can 
also have detrimental effects on host tissues
 87. Therefore, regulation of innate 
signaling  pathways  is  critical  to  maintain  immune  homeostasis.  One  form  of 
regulating these immune responses is through the diversification of protein form 
and  function.  As  mentioned  in  the  previous  chapter,  diversification  can  be 
achieved  from  a  single  genetic  locus  through  alternative  splicing  and/or 
translation, resulting in the production of multiple proteins with distinct functions. 
These processes provide an effective mechanism to either remove or add protein 
domains, which increases the functional diversity of a gene to regulate biological 
processes such as antiviral signaling. 
The antiviral RLR signaling pathway is one such innate immune pathway 
that induces inflammation and can be regulated through protein diversification
 22. 
The  gene  encoding  RIG-I,  one  of  the  receptors  for  this  pathway,  can  be 
alternatively spliced to generate two unique mature RNA transcripts
 119. The full-
length  transcript  encodes  RIG-I,  which  functions  to  detect  viruses  containing 
RNA (and in some instances DNA) genomes in the cytosol of infected cells
 145, 
146. Once RIG-I binds to viral RNA, it is activated and engages the adaptor MAVS 
to induce the expression of type I IFN, pro-inflammatory cytokines, and ISGs. 
The alternative splice variant, RIG-I sv, is a dominant negative and limits the 
signaling potential of full-length RIG-I
 119. This form of generating protein diversity ! 31!
from eukaryotic genes is a common mechanism used to control the activity of 
innate immune signaling pathways. Other examples of innate immunity genes 
with encoded splice variants that regulate signaling include MAVS, MyD88, and 
TRAM
 120-122. 
On the other hand, the process of alternative translation as a means of 
generating protein diversity has historically been considered a feature limited to 
viruses and prokaryotes
 124. While a few examples of alternative translation from 
eukaryotic  transcripts  have  been  described,  recent  genome-wide  ribosome 
profiling studies in eukaryotes indicate that polycistronic mRNAs may be more 
prevalent than previously appreciated
 133, 147. Some of the genes that encode the 
transcripts  with  alternative  start  sites  may  function  in  antiviral  innate  immune 
responses. Based on the function of innate immune variants generated through 
alternative splicing like RIG-I sv, protein variants generated through alternative 
translation might also be capable of regulating antiviral signaling. 
This chapter describes two regulators of antiviral innate immunity that are 
generated  by  alternative  translation  of  the  same  bicistronic  message.  The 
transcript  encoding  the  RLR  adaptor  protein  MAVS  produces  the  well-
characterized  full-length  (FL)  MAVS  adaptor  and  a  truncated  variant  called 
miniMAVS. A second start codon downstream of the FL MAVS start site led to 
the hypothesis that miniMAVS is translated from this alternative start site. Distinct 
experimental approaches were designed to demonstrate the bicistronic nature of 
the MAVS transcript. A genetic approach was used to mutate translational start 
sites  and  shift  the  reading  frame  of  the  transcript  to  demonstrate  alternative ! 32!
translation.  In  addition,  ribosomal  profiling  was  used  to  demonstrate  that 
ribosomes initiate translation at these unique start codons in vivo. Finally, cis-
regulatory elements within the transcript were also determined to play a role in 
controlling the synthesis of these two proteins.  
The work described in this chapter is significant in that it characterizes a 
novel level of regulation operating within the MAVS antiviral signaling gene. In 
addition, this process of alternative translation is currently considered to be a 
unique  feature  of  very  few  mammalian  genes.  This  provides  a  mandate  to 
determine  if  other  examples  of  alternative  translation  exist  in  other  “well-
characterized” genes. 
   ! 33!
RESULTS 
MAVS Point Mutations and Validation of Translational Start Sites 
In 2005, the MAVS gene was identified as an adaptor of the type-I IFN 
antiviral response to RNA viruses
 52-55. As part of its original characterization Seth 
and  colleagues  generated  a  MAVS-specific  antibody  raised  against  a  peptide 
consisting of amino acids 131-291. This antibody detected two MAVS proteins 
with apparent molecular weights of 50 and 72 kilodaltons (kDa). At the time of 
publication, it was speculated that the 50kDa variant represented a degradation 
product or processed version of the 72kDa full-length variant FL MAVS
 52. To 
date, all antiviral activities of the MAVS gene have been attributed to FL MAVS. 
The  origin  and  function  of  the  smaller  protein,  miniMAVS,  has  yet  to  be 
characterized.  These  two  MAVS  proteins  can  be  detected  in  a  number  of 
different human cell lines, indicating that the expression of both MAVS proteins is 
ubiquitous  and  likely  of  functional  relevance  (Figure  2.1A  and 
 52).  Alternative 
mRNA splicing is one process that could explain the existence of this second 
MAVS variant. However, although several MAVS splice variants exist
 120, none 
correspond  to  the  correct  size  of  miniMAVS  (~50kDa)  (data  not  shown). 
Additionally,  both  FL  MAVS  and  miniMAVS  were  expressed  from  the  MAVS 
coding region (CDS) by in vitro transcription and translation. (Figure 2.1B). Thus 
two  proteins  were  synthesized  by  translation  from  a  single  transcript  in  vitro. 
These data indicate that the two MAVS variants may also be generated from a 
single transcript in vivo and are therefore not likely to be generated by differential 
mRNA splicing. ! 34!
 
 
 
 
   
Figure  2.1  Two  MAVS  variants,  FL  MAVS  and  miniMAVS,  are 
observed by western blot 
(A) Lysates from several different human cell lines were separated by 
SDS-PAGE, and endogenous MAVS expression was detected with a 
MAVS specific antibody.  
(B) In vitro transcription and translation of the MAVS CDS compared 
with MAVS expression from 293T cell lysates using a MAVS specific 
antibody. ! 35!
The presence of a methionine at amino acid 142 of the MAVS CDS led to 
the hypothesis that miniMAVS expression is the result of translation initiation at 
an alternative start site (Figure 2.2A). Consistent with this hypothesis, initiation at 
this putative start codon (Met 142) would generate a protein corresponding to the 
molecular  weight  of  miniMAVS  (approximately  50kDa)  and  share  sequence 
homology  with  FL  MAVS.  To  determine  if  Met  142  was  required  for  the 
production of miniMAVS, I mutated the corresponding start sites by replacing the 
methionine with an alanine. Mutation of either the methionine at position 1 or the 
methionine  at  position  142  resulted  in  the  respective  loss  of  FL  MAVS  or 
miniMAVS  expression  in  vitro  (Figure  2.2B).  Furthermore,  in  vivo  stable 
expression of these mutant alleles in MAVS deficient mouse embryo fibroblasts 
(MEFs) had a similar expression pattern (Figure 2.2C). The putative start site 
corresponding to Met 142 of human MAVS is conserved among primates and 
other higher mammals (Figure 2.2D). In contrast, rodent MAVS sequences (e.g. 
Ferret, Guinea pig, mouse, rat and squirrel) do not contain a corresponding Met 
142. Thus miniMAVS appears to have evolved later in evolution than the MAVS 
protein  itself.  It  remains  to  be  determined  whether  other  putative  start  sites 
present  in  rodent  MAVS  sequences  can  function  to  produce  variant  proteins 
similar  to  human  miniMAVS.  These  results  suggest  that  the  human  MAVS 
transcript  is  bicistronic  and  that  miniMAVS  is  the  product  of  a  unique  open 
reading frame (ORF) downstream of the FL MAVS start site. 
   ! 36!
 
Figure 2.2  
miniMAVS is expressed from a second translational start site 
(A) Schematic of predicted MAVS translation products FL MAVS and 
miniMAVS  from  the  start  sites  corresponding  to  Met1  and  Met142. 
The major protein domains are shown with corresponding amino acid 
range below each domain. 
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Figure 2.2 (Continued) 
miniMAVS is expressed from a second translational start site 
(B) Point  mutations  of  translational  start  sites  at  Met1  and  Met142 
were  made  and  expressed  by  in  vitro  transcription  and  translation 
assay. The translation products were detected by immunoblot with a 
MAVS specific antibody following separation by SDS-PAGE. 
(C)  Point  mutations  of  translational start sites  at  Met1 and  Met142 
were made and expressed in vivo in MAVS-deficient mouse embryo 
fibroblasts.  The  translation  products  were  detected  by  immunoblot 
with a MAVS specific antibody. 
(D) The region surrounding Met142 of human MAVS was aligned to 
several other species. Met142 is highlighted in bold and conserved 
amino acids are highlighted with an asterisk. 
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Frame-shift Mutation in MAVS Demonstrates Bicistronic Expression From a 
Single Transcript 
The  methionine  mutations  described  above  suggest  that  miniMAVS 
expression is the result of alternative translation of a bicistronic MAVS transcript. 
However, the possibility also exists that miniMAVS is created by the proteolytic 
cleavage of FL MAVS, and that the methionine at position 142 is necessary for 
this cleavage event. If the MAVS transcript is truly bicistronic, then it should be 
possible  to  engineer  this  mRNA  to  produce  two  distinct  protein  products  that 
share  no  amino  acid  homology.  To  this  end,  a  two-nucleotide  insertion  was 
introduced between the FL MAVS and miniMAVS start sites in a MAVS construct 
containing an amino-terminal HA epitope tag (Figure 2.3A). This insertion will 
shift the reading frame of HA-tagged FL MAVS, resulting in an altered amino acid 
sequence and a truncated protein called HA-shift. However, since the insertion is 
upstream  of  the  miniMAVS  start  site,  the  reading  frame  and  amino  acid 
sequence of miniMAVS should not be affected. While the HA-shift protein could 
be detected by antibodies specific for the HA epitope tag, the shift in reading 
frame rendered the protein undetectable by the MAVS antibody (Figure 2.3B). 
Interestingly, this transcript still produced miniMAVS, as detected with the MAVS 
antibody (Figure 2.3B). The expression of these two distinct proteins from the 
same  transcript  demonstrates  the  bicistronic  nature  of  the  MAVS  mRNA. 
Additionally, the frame-shift mutation rules out the possibility that miniMAVS is 
generated by post-translational proteolysis of FL MAVS. 
   ! 39!
 
 
 
   
Figure  2.3  Frameshift  mutation  demonstrates  MAVS  is 
bicistronic 
(A)  A  schematic  of  the  HA-shift  expression  vector  containing  a 
frameshift  mutation  is  displayed  with  the  predicted  translation 
products “HA-shift” and miniMAVS. 
(B) Lysates from stable mouse embryo fibroblast cell lines expressing 
the MAVS and HA-shift constructs were separated by SDS-PAGE and 
protein  expression  was  determined  with  MAVS  and  HA  specific 
antibodies. 
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Ribosome Profile of the Endogenous MAVS Transcript Confirms Start Site 
Usage 
The experiments detailed above were carried out by genetic manipulation 
of a cloned MAVS cDNA. To investigate the bicistronic nature of the endogenous 
human  MAVS  mRNA  and  determine  whether  ribosomes  initiate  translation  at 
these start sites in vivo, a ribosome profile of MAVS mRNA from HEK293T cells 
was generated. Ribosome profiling is a strategy that utilizes deep sequencing of 
ribosome-protected  mRNA  fragments  to  investigate  different  aspects  of 
translation
  133,  135,  136.  In  conjunction  with  the  drug  harringtonine,  which  stalls 
ribosomes  at  initiation  codons,  this  technique  allows  for  the  identification  of 
functional  translational  start  sites  on  endogenous  mRNAs.  In  the  absence  of 
harringtonine,  ribosomes  were  found  throughout  the  open  reading  frame  of 
MAVS, indicating active translation and elongation (Figure 2.4). However, in the 
presence of harringtonine, ribosomes on the MAVS mRNA were predominately 
stalled at the two start sites previously identified to correspond with methionine 1 
and methionine 142 of MAVS (Figure 2.4). Therefore, the same translational start 
sites that are required for FL MAVS and miniMAVS expression in vitro are sites 
of translation initiation on the endogenous MAVS mRNA in vivo. Taken together, 
these results establish that the MAVS mRNA is bicistronic and encodes for FL 
MAVS and miniMAVS by alternative translation from two distinct start sites. 
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Figure 2.4 Ribosome profiling detects in vivo ribosome initiation 
at the FL MAVS and miniMAVS start sites 
Displayed is a pattern of ribosome initiation (harringtonine treatment) 
and elongation on the endogenous MAVS mRNA from 293T cells. ! 42!
miniMAVS Expression Requires Leaky Ribosomal Scanning 
To further understand how the expression of FL MAVS and miniMAVS is 
regulated, cis-acting elements were identified that control the expression of these 
variants.  One  mechanism  by  which  downstream  ORFs  are  expressed  from  a 
single  transcript  involves  leaky  ribosomal  scanning  through  upstream  start 
codons
 138, 143. Typically, ribosomal scanning begins at the 5’ cap of a transcript 
and translation is initiated at the first optimal start site. Optimal translational start 
sites were characterized by Marilyn Kozak and depend on the nucleotide context 
directly surrounding a start codon
 123, 139. Leaky ribosomal scanning occurs when 
the start site is suboptimal and ribosomes fail to initiate translation
 138. Under 
these  conditions,  ribosomes  will  ‘leak’  through  the  initial  start  site,  continue 
scanning  along  the  mRNA,  and  initiate  at  a  downstream  start  site.  This 
mechanism predicts that the expression of downstream proteins is dependent on 
the translational context of upstream start sites. 
If  miniMAVS  expression  requires  leaky  ribosomal  scanning,  blocking 
ribosomal  scanning  should  decrease  miniMAVS  expression.  To  test  this,  new 
start  codons  were  introduced  between  the  FL  MAVS  start  codon  and  the 
miniMAVS  start  codon  to  block  ribosomal  scanning.  Translation  initiation  at  a 
new start codon would block scanning by translating a third protein, ‘midiMAVS’, 
thus preventing ribosomes from reaching the miniMAVS start site. Introduction of 
a new start codon in a position that has a naturally strong start context (L62M) 
strongly  suppressed  miniMAVS  expression  (Figure  2.5A,  lane  2).  However, 
artificial start codons with weaker translational start contexts (G67M and E80M) ! 43!
were  leaky,  allowing  ribosomes  to  proceed  and  more  efficiently  translate 
miniMAVS (Figure 2.5A, lanes 3 and 4). These results are therefore consistent 
with the idea that miniMAVS expression relies on leaky ribosomal scanning from 
the FL MAVS start site to the miniMAVS start site. 
 
 
 
Figure  2.5  miniMAVS  expression  requires  leaky  ribosomal 
scanning 
(A)  Translational  start  sites  of  varying  strength  were  introduced  at 
Leu62,  Gly67,  and  Glu80  of  the  MAVS  CDS  to  block  ribosomal 
scanning  between  the  FL  MAVS  and  miniMAVS  start  sites.  The 
constructs were expressed in vitro and the resulting MAVS products 
were detected by immunoblot with a MAVS specific antibody 
(B)  In  vitro  expression  of  two  MAVS  CDS  constructs  containing  a 
strong (Kozak) or  weak  (anti-Kozak) translational context  at  the FL 
MAVS start site. 
 
 ! 44!
Based on these data, the translational context of any upstream start site, 
including the FL MAVS start site, could affect the expression of miniMAVS. This 
possibility was addressed by placing an artificially strong (Kozak) and weak (anti-
Kozak) translational context at the FL MAVS start site
 138. A strong translational 
context at the FL MAVS start site resulted in the high expression of FL MAVS 
compared to miniMAVS, whereas a weak translational context resulted in the 
lower expression of FL MAVS and high expression of miniMAVS (Figure 2.5B). 
These results establish the translational context surrounding the FL MAVS start 
site as a cis-regulatory element that controls the expression of miniMAVS. 
  The  above-described  experiments  all  point  to  an  important  role  for  the 
endogenous 5’ untranslated region (UTR) of the MAVS transcript in controlling 
the  expression  of  miniMAVS,  as  this  region  contains  the  natural  translational 
context of the FL MAVS start site. To address this directly, a MAVS expression 
vector  containing  the  endogenous  5’UTR  was  created.  When  MAVS-deficient 
MEFs were transiently transfected with this vector, both FL MAVS and miniMAVS 
were expressed (Figure 2.6A, lane 2) indicating that the endogenous context at 
the FL MAVS start site is sufficient for miniMAVS expression.  
   ! 45!
   
Figure  2.6  miniMAVS  expression  requires  leaky  ribosomal 
scanning 
(A) Expression of FL MAVS and miniMAVS in MAVS-deficient mouse 
embryo  fibroblasts  transfected  with  expression  containing  the 
endogenous 5’UTR of MAVS or constructs with mutated start sites for 
ORF1 or ORF3,4. 
(B) Schematic of the MAVS mRNA containing the endogenous 5’UTR 
and highlighting the three ORFs (red) that are out-of-frame with FL 
MAVS and miniMAVS. Numbers indicate the distance (in nucleotides) 
that each start site is from the FL MAVS start site. 
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An Endogenous uORF Can Regulate the Expression of miniMAVS 
Examination of all the natural start codons present within the 5’UTR and 
coding region upstream of miniMAVS suggested a mechanism by which the FL 
MAVS start site is skipped en route to translating miniMAVS. Three additional 
start codons are present within this region including one in the 5’UTR (ORF1) 
coding for an out-of-frame upstream ORF (uORF) (Figure 2.6B). The translation 
of uORFs in 5’UTRs is emerging as a means by which translation of downstream 
ORFs can be regulated
 125, 143. For example, if initiation occurs at a uORF that 
overlaps with the start site of a canonical ORF, the translating ribosome will skip 
the start codon of the canonical ORF
 143. After termination of uORF translation, 
the  ribosome  may  resume  scanning  and  re-initiate  translation  at  downstream 
ORFs. ORF1 is an overlapping uORF, predicted to initiate the translation of a 
small peptide that overlaps with the coding region of FL MAVS, terminating past 
its start site (Figure 2.6B). Translation of ORF1 might allow ribosomes to bypass 
the FL MAVS start site, resume scanning, and re-initiate at the miniMAVS start 
site. To test this, the start site of ORF1 was mutated, as were the start sites for 
ORF3  and  ORF4,  which  may  create  small  peptides  within  the  MAVS  coding 
region (Figure 2.6B). The resulting constructs were then tested for the expression 
of FL MAVS and miniMAVS in MAVS deficient MEFs. Interestingly, mutating the 
start  codon  of  ORF1  reduced  the  level  of  miniMAVS  relative  to  FL  MAVS, 
whereas  mutating  ORF3  and  ORF4  had  a  minimal  effect  on  miniMAVS 
expression (Figure 2.6A). These data suggest that ORF3 and ORF4 are likely 
bypassed by leaky scanning whereas translation of ORF1 allows ribosomes to ! 47!
skip the FL MAVS start site and facilitate the translation of miniMAVS, likely by 
re-initiation.  However, because FL MAVS is expressed when ORF1 is present 
(Figure 2.6A), skipping of the FL MAVS start site cannot occur 100% of the time. 
Therefore, leaky scanning might occur at the ORF1 start site, allowing for FL 
MAVS translation. Consistent with this hypothesis, the translational context at the 
ORF1  is  suboptimal,  suggesting  a  mechanism  by  which  leaky  scanning  may 
occur (Table 2.1). 
Table 2.1 
Start Site Name  Start Site Sequence  Start Site Strength 
ORF1  CCACCCTTCATGG  medium 
ORF2 - FL MAVS  TGAGCAGCAATGC  medium 
ORF3  ATTTTTGCAATGT  medium 
ORF4  GCAATGTGGATGT  weak 
ORF5 - miniMAVS  AGTTACCCCATGC  weak 
 
It should be noted however, that the mutation at the ORF1 start site could 
possibly  influence  the  mRNA  in  additional  ways  (e.g.  changes  in  secondary 
structure), which may contribute to altering the regulation of translation. Overall, 
our collective data reveal that cis-regulatory elements in the 5’UTR of the MAVS 
transcript  help  explain  the  relative  translation  efficiency  of  FL  MAVS  and 
miniMAVS. 
Table 2.1 Description of ORF start sites on the MAVS transcript 
The strength of each start site was determined by adherence to the 
Kozak consensus sequence. Start sites with a purine at position -3 
and a guanine at position +4 are considered strong. Start sites with 
one  of  the  above  properties  are  considered  medium,  and  those 
lacking both are considered weak. 
 ! 48!
DISCUSSION 
  Prior to this work it was well established that the MAVS genetic locus has 
a role in the defense against viral infection. Ubiquitous MAVS expression has 
been reported from many cell types further supporting its biological importance
 52. 
Interestingly, this expression has repeatedly been demonstrated to control the 
generation  of  two  proteins  from  this  single  locus
  52,  56.  The  proteins  differ  in 
apparent molecular weight and siRNA-mediated knockdown can abrogate their 
expression
 52. However, the mechanism controlling the generation of these two 
proteins had yet to be determined. This chapter demonstrates that alternative 
translation is the mechanism by which the two protein variants, FL MAVS and 
miniMAVS,  are  generated  from  a  single  mRNA  transcript.  In  addition,  cis-
regulatory  elements  within  the  transcript  control  the  expression  of  these  two 
variants through translation initiation. 
Several lines of evidence support our conclusion that the MAVS transcript 
is  bicistronic.  (1)  The  cDNA  of  MAVS  can  produce  both  FL  MAVS  and 
miniMAVS, and the molecular weight of miniMAVS does not correspond to that of 
any possible product of alternative splicing. (2) Profiling of ribosomes arrested at 
translational start sites within the endogenous MAVS mRNA revealed two start 
codons.  These  start  codons  are  predicted  to  produce  proteins  of  the  sizes 
corresponding  to  FL  MAVS  and  miniMAVS.  When  these  start  codons  were 
mutated, the resulting transcripts lost the ability to produce the corresponding 
MAVS variant. (3) Shifting the reading frame of the MAVS coding sequence at a 
site between these two start sites resulted in the production of two distinct protein ! 49!
products (HA-shift and miniMAVS). Because FL MAVS is not produced under 
these conditions, the existence of miniMAVS cannot be explained by proteolytic 
cleavage of the full-length protein. Collectively, the above observations can only 
be explained by the conclusion that FL MAVS and miniMAVS are produced from 
a bicistronic mRNA encoded by the MAVS gene. 
  The  significance  in  finding  that  the  MAVS  transcript  is  bicistronic  is 
demonstrated  by  the  scarcity  of  eukaryotic  encoded  examples  of  alternative 
translation. Changes to the process of transcription and RNA maturation have 
long  been  considered  the  predominant  form  of  generating  functional  diversity 
from a single genetic locus in eukaryotes. Although alternative translation as a 
form  of  gene  diversification  is  commonly  observed  from  viral  and  bacterial 
encoded transcripts, it has yet to be considered a common feature of eukaryotic 
genes
  124.  However,  the  MAVS  example  (in  addition  to  previously  described 
examples of eukaryotic alternative translation) highlights translation as a process 
that  can  be  used  to  generate  protein  variants  and  diversity  from  a  single 
transcript  in  eukaryotes.  Some  of  these  examples  include  transcripts  for  the 
genes encoding C/EBP, tetherin, USP18, LAP, p53, osteopontin, and PTEN
 125-
132. Both tetherin and osteopontin offer separate examples of immune regulation 
through alternative translation. The transcript encoding tetherin generates a long 
isoform l-tetherin and a short isoform s-tetherin. Due to the N-terminal truncation 
the  variant  s-tetherin  functions  as  a  negative  regulator  to  the  NF-κB  inducing 
capabilities of l-tetherin. However, both variants are capable of retaining budding 
virions,  the  primary  function  of  the  tetherin  gene
  126.  Alternative  translation  of ! 50!
osteopontin generates a full-length secreted isoform, Opn-s, and an intracellular 
isoform, Opn-i. The differential localization of these variants is dictated by the 
presence (Opn-s) or truncation (Opn-i) of a signal sequence
 131. These variants 
are  associated  with  distinct  functions  between  subsets  of  dendritic  cells 
highlighting cell type-specific control of translation. Specifically, the intracellular 
form of osteopontin is required for TLR9 driven IFNalpha expression observed in 
plasmacytoid  dendritic  cells
  148.  These  examples  support  a  model  where 
truncated  variants  generated  by  alternative  translation  have  distinct  functions. 
Whether the MAVS variants have differential function remains to be determined. 
  Regulating  the  expression  of  proteins  like  miniMAVS  from  downstream 
translational start sites is not a trivial matter during the process of translation. The 
reason for this being that mRNA translation is unidirectional and highly regulated 
following a set of steps initiated at the 5’terminal end of a transcript
 137. The 40s 
subunit of the ribosome is recruited to the 5’cap and begins processing in a 3’ 
direction scanning the nucleotide sequence for a translational start site. Once a 
start site is encountered, translation is initiated and the 60s ribosomal subunit is 
recruited  to  form  a  complete  ribosome  (80s)  complex  which  commences 
translation  elongation
  137.  Thus,  for  translation  to  occur  at  downstream  start 
codons, a mechanism must be in place to allow the ribosome to pass upstream 
start  codons.  While  some  downstream  translational  start  sites  rely  on  direct 
recruitment of the ribosome complex with an internal ribosomal entry site (IRES), 
other downstream start sites rely on ribosomes that skip or scan past upstream 
start sites
 138.  ! 51!
The work described in this chapter supports a model where miniMAVS 
expression  relies  on  uORF-mediated  start  codon  skipping  as  well  as  leaky 
ribosomal scanning. This proposed model of miniMAVS expression is based on a 
several  pieces  of  evidence.  (1)  The  expression  of  miniMAVS  is  almost 
completely abrogated when ribosomal scanning is blocked with the introduction 
of  artificial  start  sites.  If  miniMAVS  translation  relied  on  direct  recruitment  of 
ribosomes, then the expression of miniMAVS would have remained constant in 
these experiments. Therefore, it is not likely that direct recruitment of ribosomes 
at an IRES element contributes to the expression of miniMAVS. (2) Mutating the 
start site of the overlapping uORF1 resulted in a loss of miniMAVS expression. 
Overlapping  open  frames  can  mediate  start  codon  skipping  by  the  ribosome 
complex. During this process, translation can be re-initiated at downstream start 
codons once translation is terminated from the overlapping reading frame and 
the ribosome resumes scanning along the transcript
 144. (3) Mutating the start 
sites for ORF3 and ORF4 had no effect on the expression of miniMAVS. Thus 
translation  initiation  does  not  likely  occur  at  these  reading  frames,  rather 
ribosomes are likely to pass these start sites by leaky scanning. This hypothesis 
is supported by the lack of a strong translational context at the start sites for 
ORF3  and  ORF4  (Table  2.1).  These  findings  point  to  a  mechanism  where 
ribosomes initiate at uORF1 to skip the FL MAVS start codon and then scan past 
ORF3 and ORF4 to then re-initiate at the miniMAVS start site. However, this 
does not account for FL MAVS expression, which may require some degree of 
leaky scanning at uORF1. ! 52!
  In addition, there may be other mechanisms that are capable of controlling 
translation initiation at these two unique start sites. For example, other initiation 
factors may function in trans to regulate FL MAVS and miniMAVS expression. 
Global  rates  of  translation  and  start  codon  usage  can  be  affected  by  cellular 
stresses  or  viral  infection
  149,  150.  Therefore,  activation  or  deactivation  of 
translation  initiation  factors  by  IFN  signaling  or  viral  infection  could  alter 
expression of these two proteins. Future research could utilize the technique of 
ribosomal profiling to identify whether translation regulation occurs on the MAVS 
transcript  during  different  cellular  stresses.  Other  biochemical  or  genetic 
approaches  would  then  be  required  to  identify  the  factors  that  control  such 
regulation. 
  Collectively  the  work  described  in  this  chapter  demonstrates  that  the 
MAVS  transcript  is  bicistronic  and  controls  the  expression  of  FL  MAVS  and 
miniMAVS through alternative translation. Furthermore, cis-regulatory elements 
within the MAVS transcript help to control the expression of miniMAVS from a 
downstream  start  site.  While  the  proposed  expression  model  of  these  two 
proteins is based on the experiments described here, this does not exclude the 
possibility that other factors may also contribute to regulating their translation. 
For  example,  the  tertiary  structure  of  the  MAVS  transcript  (which  was  not 
addressed) could be important for regulating translation initiation. It is also likely 
that  trans-regulatory  mechanisms  contribute  to  the  control  of  FL  MAVS  and 
miniMAVS expression.  ! 53!
Whether or not FL MAVS and miniMAVS expression has more complex 
regulation will likely be of most interest in the context of their antiviral functions. 
For this reason, the antiviral function of each variant is systematically addressed 
in the following chapter. 
 
MATERIALS AND METHODS 
Generation of MAVS expression constructs 
The MAVS CDS from allele BC044952 was a gift of Z.J. Chen (UTSW). Variants 
were  cloned  into  a  pcDNA3  vector  containing  an  N-terminal  HA  tag.  Variants 
were  cloned  with  (strong  translational  context)  or  without  (weak  translational 
context) the N-terminal tag. Both used the same C-terminal restriction site XhoI, 
primer  AAAAACTCGAGCTAGTGCAGACGCCGCCGGTACAGC.  The  strong 
translational context variants were inserted into the vector with KpnI, fwd primer 
AAAAAGGTACCGCACCGTTTGCTGAAGACAAGACCTAT.  The  translational 
context at the HA start codon of this vector was as follows: AAGCTTACGATGG. 
The  weak  translational  context  variants  were  inserted  with  HindIII,  which 
removed  the  HA  tag,  fwd  primer  TTTTTAAGCTTATGCC 
GTTTGCTGAAGACAAGACCTAT. The translational context at the start codon of 
this vector was as follows: CCCAAGCTTATGC. For the Kozak and anti-Kozak 
constructs,  the  following  sequences  were  placed  directly  upstream  of  the  FL 
MAVS  start  codon:  GCCGCCACC  and  ATATATTTT.  The  sequence  used  to 
generate the 5’UTR MAVS constructs is listed in the Ensemble database under 
transcript ID number ENST00000428216. The HA-shift construct was made by ! 54!
inserting two nucleotides ‘‘TA’’ at bp number 254 of the MAVS CDS with the fwd 
primer  GTGAGCTAGTTGATCTCGTACGGACGAAGTGGCCTCTGTC.  Stable 
MAVS cell lines were generated with pMSCV2.2 IRES GFP in MAVS-deficient 
MEF  cells.  All  expression  constructs  are  available  for  purchase  online  at 
www.addgene.org where you can also find sequences and further details about 
the point mutations that were generated. 
 
MAVS Expression 
Endogenous MAVS expression was determined by western blot analysis of cell 
lysates from several human cell types grown in DMEM containing 10% serum. 
MAVS  in  vitro  expression  was  performed  using  a  coupled  transcription  and 
translation rabbit reticulocyte lysate kit (Promega) with a T7 pcDNA3 expression 
vector. MAVS in vivo expression was performed in MAVS-deficient immortalized 
MEFs  cells  cultured  in  DMEM  containing  10%  serum.  MAVS-deficient 
immortalized MEFs were a gift of Z.J. Chen (UTSW). Stable expression of the 
MAVS  and  HA-shift  constructs  was  achieved  by  genomic  integration  of  a 
pMSCV2.2 IRES GFP retroviral expression system. Transient expression of the 
5’  UTR  MAVS  constructs  was  achieved  by  Fugene  6  (Promega)  mediated 
transfection  of  a  pcDNA3  expression  vector.  The  antibodies  used  for  protein 
detection by western blot were MAVS specific (Bethyl Labs A300-782A) and HA 
specific (Roche 3F10),  
 
 ! 55!
MAVS Alignment 
The MAVS amino acid sequences from several different species were aligned 
using  the  ClustalW2  alignment  software  available  from  the  European 
Bioinformatics  Institute  online  at  http://www.ebi.ac.uk/.    The  amino  acid 
sequences  for  each  species  were  obtained  from  the  National  Center  for 
Biotechnological Information online at http://www.ncbi.nlm.nih.gov/. 
  
Ribosomal Profiling 
Ribosomal profiling was done with lysates from 293t cells that were treated or 
untreated  with  the  drug  harringtonine.  The  profiling  and  analysis  have  been 
previously described
 135. 
   ! 56!
 
 
 
 
 
 
Chapter 3 
 
miniMAVS Regulates Antiviral Signaling Events 
The substance of this chapter was previously published. 
 
Brubaker, S.W., Gauthier, A.E., Mills, E.W., Ingolia, N.T. & Kagan, J.C. 2014, 
"A bicistronic MAVS transcript highlights a class of truncated variants in antiviral 
immunity", Cell, vol. 156, no. 4, pp. 800-811. 
 
 
 
 
 
 
 
Contributions: A.E. Gauthier performed the experiments described in Figure 3.7. 
All other experiments were designed and executed by S.W. Brubaker. 
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INTRODUCTION 
The MAVS gene was originally identified based on the observation that 
overexpression of the MAVS CDS was sufficient to activate the production of 
type I IFN
 52-55. MAVS deficient mice display abrogated IFN responses and are 
therefore  more  susceptible  to  RNA  virus  infection
  15,  16.  In  addition  to  IFN 
production,  the  MAVS  gene  is  also  required  for  virus-induced  cell  death  that 
limits  viral  replication
  75,  76.  Thus  IFN  production  and  cell  death  have  been 
established as critical MAVS dependent antiviral responses. 
The  previous  chapter  established  that  FL  MAVS  and  miniMAVS  are 
generated through alternative translation of the transcript encoded by the MAVS 
gene. Previous studies reporting on the function of MAVS had yet to determine 
the antiviral signaling function of either protein individually. Therefore, it was of 
interest to determine the role of each variant in the antiviral activities attributed to 
the MAVS gene. Interestingly, the predicted MAVS cleavage product generated 
by the CVB3 protease 3C
pro resembles miniMAVS and is not capable of inducing 
an IFN response
 116. This cleavage product spanning residues 149-540 similarly 
lacks the N-terminal CARD domain, which suggests that miniMAVS may be a 
host-encoded mechanism for regulating MAVS-dependent antiviral responses.  
Changes  in  the  ratio  of  FL  MAVS  to  miniMAVS  can  also  be  detected 
following viral infection (Figure 3.1). Whereas FL MAVS became less abundant in 
infected cells over time, miniMAVS levels were not affected (Figure 3.1). Thus as 
the infection progressed, miniMAVS became the dominant MAVS variant in the 
cell. This dynamic protein regulation during an antiviral response indicates that ! 58!
each  protein  has  a  unique  role  during  the  course  of  infection,  and  justifies 
characterizing the function of each variant. 
 
This chapter characterizes the respective signaling functions of FL MAVS 
and miniMAVS. To address this question, the genetic tools developed in chapter 
two were utilized. First, the start site mutations (Figure 2.2B and C) were used to 
test each variant individually for their ability to activate a given cellular response. 
Second, changes in the translational context of the FL MAVS start site were used 
to manipulate the expression ratio of FL MAVS to miniMAVS and determine how 
they function in conjunction. Unlike FL MAVS, data in this chapter demonstrates 
that miniMAVS is not capable of inducing IFN production on it’s own. Rather, 
miniMAVS  expression  can  interfere  with  FL  MAVS-induced  IFN  expression.  
While these two variants are capable of antagonizing one another in the context 
of IFN production, they are each capable of positively inducing the antiviral cell 
death response.   
Figure 3.1  
The ratio of FL MAVS to miniMAVS changes following infection 
Western  blot  analysis  of  endogenous  FL  MAVS  and  miniMAVS 
expression in 293T cells following SeV infection. ! 59!
RESULTS 
miniMAVS Interferes With FL MAVS mediated IFN production 
To  determine  a  role  for  miniMAVS  in  the  antiviral  IFN  response,  the 
production of type I IFN was measured following expression of the MAVS start 
site  mutants  in  293T  cells.  When  only  the  FL  MAVS  variant  (M142A)  was 
expressed,  robust  production  of  type  I  IFN  was  observed  (Figure  3.2A). 
Conversely, when only miniMAVS (M1A) was expressed there was no induction 
of type I IFN. In addition, a miniMAVS deletion mutant lacking the C-terminal 
localization signal (M1A-500) was not capable of inducing the production of IFN 
(Figure 3.2A and 
 52). The results of this experiment suggest that FL MAVS is 
sufficient to positively regulate the production of IFN whereas miniMAVS is not 
sufficient  to  activate  the  pathway.  However,  when  the  two  variants  were 
expressed in conjunction (MAVS) there was a decrease in type I IFN production 
compared  to  FL  MAVS  expression  alone  (Figure  3.2A).  To  corroborate  these 
findings,  the  phosphorylation  of  STAT1,  an  indicator  of  IFN  signaling
  151,  was 
monitored  over  the  course  of  24hrs  following  transfection.  Compared  to  FL 
MAVS expression alone (M142A), cells expressing both MAVS variants (MAVS) 
contained lower levels of phosphorylated STAT1 over time (Figure 3.2B). This 
difference in signaling activity between cells expressing FL MAVS alone and cells 
expressing both MAVS variants was not the result of differential expression of FL 
MAVS. Indeed, western analysis indicated comparable expression of FL MAVS 
when  expressed  alone  (M142A)  or  when  expression  in  conjunction  with 
miniMAVS  (MAVS)  (Figure  3.2B).  Taken  together,  these  results  suggest  that ! 60!
miniMAVS  antagonizes  the  signaling  function  of  FL  MAVS  and  inhibits  IFN 
production.  
 
 
 
Figure 3.2 miniMAVS interferes with IFN signaling 
(A) Type I IFN production was measured following the expression the 
miniMAVS  alone  (M1A),  FL  MAVS  alone  (M142A),  or  the  two  in 
conjunction  (MAVS).  In  addition,  IFN  production  from  a  miniMAVS 
construct lacking the TM domain was determined (M1A-500). ! 61!
 
 
 
 
 
 
 
   
Figure 3.2 (Continued) miniMAVS interferes with IFN signaling 
(B) Following transient transfection of the constructs described in (A), 
the  expression  of  MAVS  variants  and  STAT1  phosphorylation  was 
monitored over time by western blot. 
(C) IFN production and (D) STAT1 phosphorylation were monitored 
as in (A and B). However the transient expression constructs contain 
a  comparatively  weaker  translational  context  at  the  FL  MAVS  start 
site. As a result, there is more leaky scanning and a higher ratio of 
miniMAVS to FL MAVS expression (compare MAVS conditions from 
B and D). 
***p < 0.001 by ANOVA with Tukey’s multiple comparison test. Error 
bars represent standard deviation. ! 62!
To  more  directly  test  the  hypothesis  that  miniMAVS  can  inhibit  the 
production of IFN, an expression construct with a weak translational context at 
the  FL  MAVS  start  site  was  characterized.  Due  to  leaky  scanning,  this  weak 
translational context is predicted to increase the ratio of miniMAVS to FL MAVS 
in the cell, and this increase in ratio was predicted to further inhibit the production 
of  type  I  IFN.  As  expected,  the  weak  translational  context  resulted  in  higher 
abundance  of  miniMAVS  relative  to  FL  MAVS  when  both  variants  were 
expressed (MAVS, Figure 3.2D), as compared to the experiments using MAVS 
with a strong translational context (Figure 3.2B). Remarkably, when both variants 
were expressed in conjunction (MAVS) with this weak translational context, the 
effect was a complete abrogation of IFN production and STAT1 phosphorylation 
(Figure 3.2C and D). However, under the same conditions, when FL MAVS was 
expressed alone (M142A), a robust production of IFN and STAT1 activation was 
observed (Figure 3.2C and D). Taken together, these data reveal miniMAVS as 
an inhibitor of FL MAVS signaling and that the ratio of FL MAVS to miniMAVS 
determines whether an antiviral response will occur. 
To further test miniMAVS inhibition of IFN signaling, expression constructs 
that  more  closely  mimicked  the  natural  MAVS  transcript  were  examined. 
Specifically, the activation of IFN signaling following expression from constructs 
containing the endogenous 5’UTR and MAVS CDS were examined. As described 
in chapter two, ORF1 in the 5’UTR of the transcript can regulate the expression 
of miniMAVS, and when mutated, there is a decrease in miniMAVS expression 
(Figure 2.6A). Thus mutating the ORF1 start site would be expected to result in ! 63!
increased IFN production. Consistent with this idea, when compared to the wild-
type  (WT)  5’UTR  construct,  expression  of  the  uORF1  mutant  resulted  in 
increased STAT1 activation (Figure 3.3A and B). These data further establish 
that miniMAVS interferes with the FL MAVS IFN response and identify uORF1 as 
a regulator of both the expression and function of miniMAVS. 
 
 
Figure 3.3 STAT1 activation after transient expression of MAVS 
containing the endogenous 5’UTR and uORF mutations 
(A)  Western  blot  analysis  of  STAT1  phosphorylation  and  MAVS 
expression  following  transient  transfection  of  the  indicated  MAVS 
constructs  
(B) The ratio of STAT1 phosphorylation to FL MAVS expression was 
quantified  by  densitometry.  Densitometry  is  from  a  representative 
image of an experiment done in triplicate. ! 64!
Having  established  regulatory  effects  of  FL  MAVS  and  miniMAVS  on 
antiviral signaling, the differential expression of the two proteins would also be 
predicted to affect viral replication. Whereas the expression of miniMAVS alone 
(M1A) had little effect on the replication of vesicular stomatitis virus (VSV), FL 
MAVS expression alone (M142A) dramatically reduced VSV replication (Figure 
3.4). Interestingly, expression of the two proteins in conjunction (MAVS, as in 
Figure  3.2D)  was  less  effective  at  limiting  viral  replication  as  compared  to 
expression of FL MAVS alone (Figure 3.4). These data therefore establish that 
miniMAVS acts to restrict the signaling functions of FL MAVS, the physiological 
consequence of which is that FL MAVS is less able to create an antiviral cellular 
state. 
Figure 3.4 The effect of miniMAVS expression on viral replication 
293t cells were transfected with the MAVS constructs from Figure 3.2 
C.  24  hours  post  transfection  the  cells  were  infected  with  VSV-
encoding  firefly  luciferase.  As  a  measure  of  viral  replication,  the 
luciferase activity  was determined  7 hours  following  infection. Error 
bars represent standard deviation of an experiment in triplicate. ! 65!
miniMAVS Does Not Prevent the Polymerization of FL MAVS 
During  viral  infections,  large  aggregates  of  FL  MAVS  form  that  recruit 
downstream  enzymes  to  promote  the  expression  of  type  I  IFNs
  56.  It  was 
therefore possible that miniMAVS restricts the signaling functions of FL MAVS by 
preventing  the  formation  of  these  large  protein  aggregates.  To  address  this 
possibility, FL MAVS was expressed alone or in conjunction with miniMAVS, and 
FL  MAVS  aggregates  were  detected  following  sucrose  gradient 
ultracentrifugation. For these studies, the expression constructs containing the 
weak translational context from Figure 3.2 were used, as under these conditions, 
miniMAVS completely abrogated the production of IFN. When FL MAVS alone 
(M142A)  was  expressed,  aggregates  of  FL  MAVS  could  be  detected  at  the 
bottom of the sucrose gradient (Figure 3.5A). This was expected because the 
expression of FL MAVS alone results in the production of IFN (Figure 3.2C), and 
it is thought that IFN signaling is a result of MAVS aggregation
 56. Interestingly, 
when both FL MAVS and miniMAVS were expressed in conjunction (MAVS), the 
formation of FL MAVS aggregates was also detected (Figure 3.5A). This was 
surprising  because,  under  these  conditions,  miniMAVS  completely  blocks  the 
production of IFN (Figure 3.2C). These data suggest that miniMAVS cannot block 
FL  MAVS  aggregate  formation,  even  under  conditions  where  the  signaling 
functions of FL MAVS are completely prevented. Consistent with the idea that 
miniMAVS  does  not  influence  the  aggregate-forming  activity  of  its  full-length 
counterpart; in response to Sendai virus infections, endogenous miniMAVS does ! 66!
not co-sediment with FL MAVS aggregates (Figure 3.5B). Thus, miniMAVS is 
neither a component of FL MAVS aggregates nor does it regulate their formation. 
 
 
 
 
 
   
Figure 3.5 miniMAVS does not prevent FL MAVS polymerization 
(A) Crude mitochondria (P5) isolated from 293T cells transfected with 
MAVS  or  the  M142A  point  mutant  were  separated  by  sucrose 
gradient  ultracentrifugation.  FL  MAVS  polymers  segregated  to  the 
bottom  of  the  gradient  (right)  and  were  detected  by  SDS-PAGE 
followed by immunoblot with a MAVS antibody. 
(B) 293t cells were infected with SeV and crude mitochondrial extracts 
were  separated  by  sucrose  gradient  centrifugation  to  detect  MAVS 
polymers by SDS-PAGE and MAVS immunoblot. ! 67!
miniMAVS Can Interact With the Downstream Signaling Enzymes TRAF2 
and TRAF6 
Aggregates of FL MAVS promote antiviral signaling by recruitment of the 
E3 ubiquitin ligases TRAF2 and TRAF6
 57. Because miniMAVS was not capable 
of blocking FL MAVS aggregation, I hypothesized that it may interfere with signal 
transduction by interacting with these downstream signaling proteins. To test this, 
I  used  a  Flag-tagged  miniMAVS  expression  vector  and  tested  Flag-
immunoprecipitates for the presence of endogenous TRAF2 and TRAF6. Both 
endogenous  TRAF  proteins  interacted  specifically  with  Flag-miniMAVS  as 
compared to Flag-tagged RIG-I or a vector control (Figure 3.6A). Flag-tagged 
TRAF6 formed a modest complex with endogenous TRAF2. Additionally, when 
Flag-miniMAVS  was co-expressed  with  HA-TRAF6  or  HA-TIRAP,  TRAF6  was 
detected in the Flag-immunoprecipitates, whereas the TLR adaptor TIRAP was 
largely absent (Figure 3.6B). Taken together, these data indicate that miniMAVS 
forms a complex with TRAF proteins that are known to promote antiviral signaling 
and IFN production. A possible mechanism of miniMAVS function may therefore 
be  proposed  whereby  two  protein  complexes  exist  that  contain  MAVS.  One 
complex consists of FL MAVS aggregates and TRAF proteins and is capable of 
activating type I IFN expression
 57. The second complex consists of miniMAVS 
and  the  same  TRAFs  (Figure  3.6)  yet  is  incapable  of  activating  type  I  IFN 
expression.  The  regulation  of  the  functional  competition  between  these  two 
complexes remains an open area of inquiry. 
 ! 68!
 
 
 
 
 
   
Figure 3.6 miniMAVS interacts with TRAF2 and TRAF6 
(A) 293T cells were transfected with Flag-tagged miniMAVS, RIG-I, or 
TRAF6  and  Flag-immunoprecipitates  were  probed  for  endogenous 
TRAF2 and TRAF6. 
(B)  HA-tagged  TRAF6  or  TIRAP  expression  vectors  were  co-
transfected  into  293T  cells  with  a  3xFlag-miniMAVS  expression 
vector. Immunoprecipitates were collected with a Flag specific affinity 
gel. The presence of TRAF6 within the precipitant was determined by 
an immunoblot with an HA antibody. ! 69!
miniMAVS Positively Regulates Cell Death 
In addition to activating antiviral gene expression, MAVS can promote cell 
death upon overexpression or in response to certain viral infections
 75, 76. As with 
the IFN response, the role of miniMAVS in cell death is unknown. To test whether 
each  MAVS  variant  is  sufficient  to  activate  cell  death,  the  variants  were 
overexpressed  in  293T  cells  an  monitored  for  cell  death.  When  both  variants 
were overexpressed in conjunction (MAVS), there were visible signs of cell death 
compared to cells transfected with a vector control (Figure 3.7A). Interestingly, 
when miniMAVS (M1A) or FL MAVS (M142A) were expressed alone, cell death 
was also observed. Quantification of the number of cells that detached from the 
tissue culture plate revealed that FL MAVS and miniMAVS induce comparable 
amounts of cell death at 30 hours following transfection (Figure 3.7B, left panel). 
However,  by  48  hours  cell  death  induced  by  FL  MAVS  exceeded  that  of 
miniMAVS (Figure 3.7B, right panel). The increase in cell death induced by FL 
MAVS may be the result of secreted IFNs, which can positively influence cell 
death
  152.  Interestingly,  a  miniMAVS  deletion  mutant  lacking  the  C-terminal 
localization domain (M1A-500) did not show signs of cell death compared to the 
vector control (Figures 3.7). Based on these data, miniMAVS may function to 
positively regulate cell death in a localization-dependent, but IFN-independent 
manner. 
   ! 70!
 
 
 
 
   
Figure 3.7 FL MAVS and miniMAVS induce signs of cell death 
(A) Micrographs of 293T cells 48 hours after transfection with MAVS 
and start site point mutant expression vectors. The MAVS M1A-500 
construct lacks the C-terminal transmembrane domain. 
(B) The number of floating cells was quantified at 30 and 48 hours 
following transfection as in (A). Experiment was performed in triplicate 
and the error bars represent the standard deviation. 
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To  further  investigate  the  induction  of  cell  death  by  FL  MAVS  and 
miniMAVS, two hallmarks of this process were also assessed. Programmed cell 
death,  including  apoptosis  and  necroptosis,  is  often  characterized  by  the 
fragmentation  of  genomic  DNA
  153.  Both  miniMAVS  (M1A)  and  FL  MAVS 
(M142A)  induced  the  fragmentation  of  genomic  DNA  following  expression  in 
293T cells (Figure 3.8). In support of our visual observations of cell death, the 
miniMAVS mutant (M1A-500) lacking the localization signal was not capable of 
inducing  DNA  fragmentation.  As  a  control,  DNA  fragmentation  induced  by  a 
known regulator of cell death, the TLR adaptor TRIF was also monitored (Figure 
3.8) 
 154, 155. 
 
 
Figure 3.8 FL MAVS and miniMAVS induce DNA fragmentation 
Genomic  DNA  fragmentation  was  detected  24  hour  following 
transfection  of  MAVS  and  TRIF  expression  vectors.  Genomic  DNA 
was separated on a 2% agarose gel. ! 72!
Prior  to  the  commitment  toward  cell  death  and  DNA  fragmentation, 
caspases  become  activated  and  subsequently  cleave  a  variety  of  target 
substrates  to  carry  out  apoptosis
  156.  PARP  is  one  of  the  targets  of  these 
activated caspases, making detection of the cleaved product of PARP a reliable 
marker for cell death. Therefore, to further investigate the induction of cell death 
by FL MAVS and miniMAVS, the induction of PARP cleavage individually was 
determined. At several time points following the expression of both variants in 
conjunction (MAVS), the cleaved product of PARP was observed (Figure 3.9). 
Again,  TRIF  was  used  as  a  positive  control  for  cell  death  to  monitor  PARP 
cleavage. In agreement with our DNA fragmentation results, PARP cleavage was 
detected  in  cells  individually  expressing  either  miniMAVS  (M1A)  or  FL  MAVS 
(M142A)  but  not  cells  expressing  the  improperly  localized  miniMAVS  mutant 
M1A-500. These data indicate that unlike their antagonizing activities toward IFN 
expression, FL MAVS or miniMAVS can both promote PARP cleavage and cell 
death.  Although  the  MAVS  localization  domain  directs  this  adaptor  to 
mitochondria, peroxisomes, and MAMS
 58, 59, the central role of mitochondria in 
programmed cell death led us to speculate that the death-inducing signal from 
MAVS probably emerges from this organelle
 153, 156. When another mitochondrial 
protein  (NLRX1)
  88  was  examined  in  the  PARP-cleavage  assay,  no  PARP 
cleavage  was  observed  (Figure  3.9).  Therefore,  the  observed  cell-death 
phenotype is specific to FL MAVS and miniMAVS and is not a general response 
to  ectopic  expression  of  another  mitochondrial  membrane  protein.  Thus,  in ! 73!
addition to their antagonistic actions in regulating IFN expression, FL MAVS and 
miniMAVS can each promote the cell death response. 
 
 
 
 
 
 
   
Figure 3.9 FL MAVS and miniMAVS induce PARP cleavage 
Cell lysates were collected at 24, 30, and 48 hours post-transfection 
of MAVS, the translational start site point mutants, NLRX1, and TRIF. 
PARP  cleavage  and  MAVS  expression  was  determined  by 
immunoblot following SDS-PAGE. 
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DISCUSSION 
  The  regulation  of  innate  immune  signaling  pathways  is  crucial  for  the 
defense  against  pathogenic  infection  as  well  as  the  maintenance  of  immune 
homeostasis
 1, 87. Hundreds of genes and regulatory mechanisms are involved in 
controlling the response to RNA viruses alone. Previously, the MAVS gene has 
been  demonstrated  to  play  a  role  in  the  defense  against  viral  pathogens. 
However, as demonstrated in chapter two, this gene encodes a transcript that 
produces two alternatively translated variants, FL MAVS and miniMAVS. The role 
that  these  variants  play  in  the  antiviral  response  was  unknown.  This  chapter 
demonstrates  that  the  variants  FL  MAVS  and  miniMAVS  have  differential 
functions in the context of antiviral response mechanisms. Specifically, FL MAVS 
functions as a positive regulator of IFN production, which is consistent with many 
previously  published  functional  studies  characterizing  the  MAVS  gene.  In 
contrast, miniMAVS cannot activate the production of IFN but it can inhibit IFN 
production induced by its full-length counterpart. Interestingly, both variants are 
capable of inducing cell death. 
  Chapter one discusses regulators of MAVS that are believed to function 
through  direct  interaction.  While  the  data  in  this  chapter  demonstrates  that 
miniMAVS is a negative regulator of FL MAVS induced IFN production, it does 
not appear that miniMAVS interacts with polymerized FL MAVS as a mechanism 
of  action.  Several  pieces  of  evidence  allow  us  to  make  this  conclusion.  (1) 
miniMAVS does not contain the CARD domain, which is required for homotypic 
interactions and MAVS polymerization (Figure 2.2). Therefore miniMAVS is not ! 75!
likely to interact with the polymerized forms of FL MAVS. (2) miniMAVS was not 
found  to  associate  with  the  aggregates  of  FL  MAVS  polymers  following  viral 
activation (Figure 3.5). (3) Co-immunoprecipitation experiments failed to show an 
interaction between FL MAVS and miniMAVS (data not shown). The possibility 
remains that miniMAVS and FL MAVS interact with each other at steady state in 
the absence of infection, however in the context of active IFN signaling, it does 
not appear that miniMAVS interacts with the FL MAVS polymers. 
  Since  miniMAVS  can  induce  cell  death,  one  could  speculate  that  this 
process  functions  to  limit  IFN  production.  However,  the  IFN  and  cell  death 
responses appear to be completely independent of one another, and the timing 
of each does not support such a hypothesis. Whereas IFN production can be 
detected very rapidly, the induction of cell death occurred over a longer period of 
time. Therefore in this case, the control of IFN production by cell death would be 
anachronistic  and  thus  not  a  likely  mechanism  of  miniMAVS-mediated  IFN 
control.  
  Future studies will be needed to more definitively address the mechanism 
by which miniMAVS inhibits FL MAVS dependent IFN production. Regardless of 
the mechanism of action, miniMAVS provides a clear demonstration of immune 
regulation  through  alternative  translation.  Many  other  examples  of  immune 
regulation generated by alternative translation may also exist but have yet to be 
identified. The following chapter describes a ribosome-profiling screen that was 
established in an effort to make such identifications.  
 ! 76!
MATERIALS AND METHODS 
MAVS Expression and Type I IFN Bioassay 
The MAVS constructs were cloned into pcDNA3 expression constructs. Transient 
expression  was  achieved  in  293T  cells  cultured  in  DMEM  (10%  serum)  by 
Fugene  6  (Promega)  mediated  transfection.  The  type  I  IFN  bioassay  was 
performed as previously described 
 58. Briefly, cell supernatants were collected 
following gene expression and incubated with an IFN-luciferase reporter cell line. 
Luciferase  reporter  activity  and  responsiveness  was  standardized  to  known 
concentrations of recombinant human IFN-beta. 
 
Antibodies  
The antibodies used for western blot analysis were as follows: MAVS (Bethyl 
Labs A300-782A), pSTAT (BD 612132), PARP (BD 611038), HA (Roche 3F10), 
Flag  (Biolegend  637301)  TRAF2  Cell  Signaling  (C192),  and  TRAF6  Abcam 
33915.  
 
Viral Infections 
The Cantell Strain of SeV (Charles River Laboratories) was used to infect cells at 
a concentration of 50 U/ml.  A VSV strain containing a firefly luciferase reporter 
was provided as a gift of Sean Whelan. Cells were infected with the VSV-firefly-
luc at a multiplicity of infection (moi) = 1.  Cells and virus were incubated in media 
lacking serum at low volume for 1 hour at the start of each infection. 
 ! 77!
Co-immunoprecipitations 
miniMAVS was cloned into a 3xFlag CMV expression construct and transiently 
transfected  into  293t  cells.  Flag-vector,  Flag-RIG-I,  and  Flag-TRAF6  were 
transfected in parallel as controls. Flag immunoprecipitates were isolated with 
M2-affinity gel (Sigma) and eluted with a FLAG peptide. 
 
Statistical Analysis 
Prism (GraphPad) was used to create all figures and perform all statistical 
analysis. Error bars indicate the standard deviation. 
 
Detection of FL MAVS Polymers by Sucrose Gradient Ultracentrifugation  
Sucrose  gradient  ultracentrifugation  was  performed  as  previously 
described
  56.  Briefly,  5x10
5  293T  cells  were  plated  in  10  cm  dishes  and 
transfected  with  MAVS  expression  vectors.  Ten  hours  after  transfection,  cells 
were lifted and lysed by dounce homogenization. A P5 crude mitochondrial pellet 
was  obtained  and  solubilized  in  1%  DDM
  56.  Soluble  mitochondria  were  then 
loaded onto a 30%–60% sucrose gradient and centrifuged for 2 hour at 170,000 
g at four degrees Celsius. Fractions were then removed from the gradient with 
the bottom fraction containing MAVS polymers. 
 
Detection of DNA Fragmentation 
Fragmented genomic DNA was observed by agarose gel electrophoresis 
following  phenol  chlororform  extraction
 157.  24  hours  following  transient  MAVS ! 78!
expression cells were collected, lysed, and the genomic DNA was isolated and 
analyzed as described.   ! 79!
 
 
 
 
 
 
Chapter 4 
 
Genome-wide Ribosomal Profiling Predicts a Set of mRNAs that Encode 
Regulators of Innate Immunity from Alternative Start Sites  
The substance of this chapter was previously published. 
 
 
Brubaker, S.W., Gauthier, A.E., Mills, E.W., Ingolia, N.T. & Kagan, J.C. 2014, 
"A bicistronic MAVS transcript highlights a class of truncated variants in antiviral 
immunity", Cell, vol. 156, no. 4, pp. 800-811. 
 
 
 
 
 
Contributions: The data for this chapter was generated by ribosomal profiling 
experiments carried out by S. W. Brubaker and E. W. Mills. N.T. Ingolia 
contributed data analysis and figure design. 
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INTRODUCTION 
  Based on the work described in Chapter two, MAVS can now be added to 
a  small  list  of  eukaryotic  genes  known  to  produce  bicistronic  transcripts.  FL 
MAVS and miniMAVS are two protein variants generated from a single transcript 
during the process of translation. Recently a new technique termed ribosome 
profiling has been developed to study the process of translation in vivo
 135. This 
technique utilizes deep sequencing of mRNA transcripts that are protected by the 
ribosome complex to determine which transcripts are actively being translated. 
As  described  in  chapter  two,  in  conjunction  with  the  drug  harringtonine,  this 
technique can be used to monitor translation initiation and determine start codon 
usage. In one recent study, global translation initiation and start codon usage 
was  determined  in  mouse  embryonic  stem  cells
  133.  This  study  indicated  that 
there might be many more examples of eukaryotic transcripts in which translation 
is initiated from more than one start codon. Therefore alternative translation of 
mRNA transcripts may be a generalized mechanism for regulating gene function. 
  We considered the possibility that alternative translation commonly occurs 
on  transcripts  encoded  by  antiviral  innate  immunity  genes.  This  could  be  a 
mechanism for regulating antiviral responses in the face of changes to translation 
that  occur  during  viral  infection
  150, 158.  Both  virus  encoded  and  host  encoded 
mechanisms  can  alter  the  translational  landscape  during  viral  infection  as  a 
means of ensuring viral protein synthesis or preventing it. Ribosome profiling is 
an unbiased approach to studying translation globally and an effective way to 
generate  a  candidate  list  of  genes  that  may  also  encode  transcripts  that  are ! 81!
alternatively  translated.  Therefore,  we  set  out  to  perform  a  ribosome  profiling 
screen to determine if other antiviral innate immune genes encode transcripts 
that are alternatively translated.  
  As  mentioned  above,  a  previously  published  report  conducted 
translational start site analysis by ribosomal profiling of mouse embryonic stem 
cell  transcripts.  However,  miniMAVS  alternative  translation  was  characterized 
with the human encoded MAVS transcript. In addition, the translational start site 
and methionine at position 142 is not conserved between mouse and human 
transcripts  (chapter  2).  Therefore,  while  many  translational  start  sites  are 
conserved,  there  is  likely  to  be  some  specificity  between  species.  For  these 
reasons,  the  translational  start  site  analysis  described  in  this  chapter  was 
performed with transcripts from a human cell type. The choice of cell type within 
a  species  was  also  considered  due  to  differences  in  transcript  expression 
between cell types. While many antiviral innate immune genes are ubiquitously 
expressed  between  cell  types,  monocytes  of  hematopoietic  lineage,  such  as 
macrophages and dendritic cells, have a higher percentage of innate immune 
gene expression. Thus the monocytic cell line U937 derived from a histiocytic 
lymphoma was chosen for translational start site analysis by ribosomal profiling
 
159.  These  cells  differ  from  primary  human  monocytes  in  that  they  have 
transformed into an immortal state and express genes required for immortality. 
As  these  cells  retain  gene  expression  and  phenotypic  similarities  to  primary 
monocytes,  they  are  a  suitable  substitute  for  the  study  of  monocyte  protein 
mRNA translation
 159. However, as described for the gene encoding osteopontin
 ! 82!
131, differences in start site usage can also exist between cell types. Therefore, 
the start codon usage identified in this study may differ from the translational start 
codons  used  in  other  cell  types.  This  chapter  describes  the  results  of  this 
ribosome  profiling  study  done  in  collaboration  with  the  laboratory  of  Nicholas 
Ingolia. 
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RESULTS 
Global Start Site Analysis 
In the presence of harringtonine, ribosome profiling identified 14,336 sites 
of  active  translation  initiation  present  on  8,893  transcripts  expressed  in  U937 
cells (A list of these start sites can be found online in the supplemental data table 
published here
 86). Therefore, many of the expressed transcripts contain more 
than one  functional translation start site (Figures 4.1A). The predicted protein 
products generated from these start sites can be classified into different groups 
relative to the reading frame of the annotated CDS. These groups include start 
sites  for  the  generation  of  the  canonical  CDS,  uORFs,  internal  out-of-frame 
products, truncations, and extensions (Figure 4.1B). As an example, the human 
MAVS  transcript  characterized  in  chapter  two  has  a  “canonical”  start  site 
responsible for translation of FL MAVS and a “truncation” start site responsible 
for miniMAVS translation. 
One aspect of the host-mediated changes in translation that occur during 
viral infection can be attributed to the interferon-stimulated expression of protein 
kinase  RNA-activated  (PKR)
  158.  This  is  one  of  four  kinases  that  target  the 
translation initiation factor eIF-2α, which prevents the initiation factor from being 
recycled  and  leads  to  a  general  inhibition  of  translation.  To  determine  host-
mediated changes in the rate of translation and start site usage, U937 cells were 
treated with recombinant human IFN beta and ribosome profiles were compared 
with  those  of  untreated  cells.  Unfortunately,  the  results  of  this  comparison ! 84!
indicated little to no significant change in the rate of translation or in start site 
usage following IFN treatment (data not shown). 
 
 
 
 
 
 
 
 
   
Figure 4.1 Translation start site analysis by ribosomal profiling 
(A) The fraction and number of genes that were detected to have one 
or more translational start sites 
(B)  Classification  chart  of  each  predicted  translation  product  as  it 
relates to the annotated coding sequence of a gene. ! 85!
The  work  on  MAVS  described  in  chapters  2  &  3  highlighted  the 
importance of protein diversification via alternative translation. Thus transcripts 
containing  start  sites  predicted  to  result  in  the  production  of  variant  protein 
isoforms such as truncations and extensions were of interest because they lose 
or gain some amino acid sequence relative to the canonical CDS. This can alter 
the function of the variant as in the case of miniMAVS, which lacks the CARD 
domain present in the amino terminus of FL MAVS. Our analysis indicated that 
14% of the start sites identified in U937 cells are predicted to encode either a 
truncation or an extension, and a fraction of the genes are predicted to translate 
more than one isoform in U937 cells (Figure 4.2A). In addition, our profiling data 
indicate  that  truncations  are  more  prevalent  than  would  be  expected  from 
random  chance.  Based  on  the  use  of  triplet  codons,  a  third  of  possible  start 
codons would be in-frame with the canonical ORF and two-thirds would be out-
of-frame.  If  start-site  selection  were  random,  we  would  expect  a  1:2  ratio  of 
truncations to internal out-of-frame ORFs. However, we observed about a 4:3 
ratio in the favor of truncations (Figure 4.2B). Additionally, truncations appear to 
be more frequent than extensions, suggesting that these variants may have more 
biological significance (Figure 4.2C). 
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Figure 4.2 Translation start site analysis by ribosomal profiling 
(A) The fraction and number of genes that were detected to have one 
or more protein isoform. 
(B  and  C)  Venn  diagrams  showing  genes  containing  canonical, 
truncation, and (B) internal out-of-frame or (C) extension start sites. ! 87!
Innate Immune Genes with Alternative Start Sites 
Several genes involved in antiviral innate immunity were identified by our 
analysis to potentially produce truncated variants from alternative translational 
start  sites.  The  patterns  of  ribosomal  profiling  indicate  that,  like MAVS,  IFIH1 
(also known as MDA-5), MX2, IFITM2, and TRIM25 ribosomes are stalled at start 
sites  downstream  of  a  respective  canonical  start  site  in  the  presence  of 
harringtonine (Figures 4.3 A-D). In addition to stalled ribosomes, other factors 
make some of these transcripts good candidates for alternative translation such 
as the presence of overlapping uORFs or the lack of evidence for splice variants 
that would explain these start sites. As in the case for IFIH1 and MX2 (Figure 4.3 
A-B), the identified overlapping uORFs may help to explain translation initiation 
from downstream start sites. However, the number of transcripts with potential 
alternative start sites comprise only a fraction of all the antiviral innate immunity 
transcripts monitored and most translate only a single canonical protein product, 
such  as  DDX58  (RIG-I)  and  TMEM173  (STING)  (Figures  4.3E  and  4.3F).  In 
addition to truncation variants, extension variants as well as other non-immune 
related  genes  might  also  be  of  biological  interest.  Protein  products  that  are 
generated from start sites that are out-of-frame with a canonical protein may also 
be of biological significance. These products however would not share any amino 
acid sequence with the canonical protein and therefore may be more difficult to 
characterize  with  distinct  biological  implications  compared  to  the  canonical 
protein.  A  searchable  list  of  all  the  U937  start  sites  identified  in  this  study  is 
available online
 86.   ! 88!
 
   
Figure 4.3 Ribosome profiles of select antiviral genes 
(A-F)  The  patterns  of  ribosome  elongation  (+CHX)  and  initiation 
(+Harr)  are  shown  for  several  transcripts  involved  in  antiviral 
immunity.  The  translation  products  predicted  by  harringtonine 
treatment  are  shown  below  each  profile.  Canonical  translation 
products are in grey, truncations in green, uORFs in red, and internal 
out-of-frame translation products are in orange. ! 89!
DISCUSSION 
  This chapter describes the global analysis of translation initiation from the 
U937 monocytic cell line. In addition, the effect of IFN signaling on translation 
was also tested in these cells. Unfortunately, the comparison with IFN treatment 
yielded  no  detectable  changes  in  either  the  rate  of  translation  or  in  start  site 
usage.  This  result  was  somewhat  of  a  surprise  based  on  interferon-inducible 
PKR-mediated changes to translation during viral infection
 158. However, there 
are a few explanations as to why no change was observed in our analysis. First, 
our treatment time (8hr) was based off of IFN responsiveness detected at the 
transcript level. It is possible that the effect of IFN treatment on translation may 
be  transient,  and  thus  may  have  resolved  prior  to  our  analysis.  Secondly, 
changes in translation associated with viral infection require PKR activation in 
addition to its IFN induced expression
 158. Furthermore, the kinase activity of PKR 
requires the presence of a double stranded RNA ligand. Thus in our experimental 
setup,  the  absence  of  a  double  stranded  RNA  ligand  provides  a  potential 
explanation as to why we observed no change in translation.  
While  the  data  indicated  no  significant  changes  in  translation  from  IFN 
treatment alone, a global list of steady state translational start sites from U937 
monocyte transcripts was generated. This analysis suggests that FL MAVS and 
miniMAVS are not the only regulators of antiviral innate immunity encoded by a 
polycistronic transcript. From the start sites identified, a list of candidate antiviral 
innate immune genes was created (Figure 4.3) that may encode polycistronic 
transcripts. Additional work is needed to verify that these genes do in fact encode ! 90!
transcripts  that  are  polycistronic,  because  it  remains  possible  that  these  start 
sites are found on uncharacterized splice variants. Furthermore, each start site 
should be mutated to determine an effect on protein expression. The abundance, 
stability,  and  function  of  the  predicted  protein  variants  will  also  need  further 
verification  to  determine  whether  they  are  regulators  of  innate  immunity  like 
miniMAVS. Regardless, this analysis highlights the potential existence of a class 
of bicistronic regulators of antiviral innate immunity. 
  As discussed above, the usage of translational start sites on transcripts 
may  differ  between  species,  cell  type,  or  even  environmental  condition.  For 
example  the  gene  encoding  Osteopontin  provides  an  example  of  cell  type 
specific  start  codon  usage
  131  however,  another  example  of  differences  in 
translation have been observed from the gene encoding ECSIT. The transcript 
encoding  this  adapter  of  toll  pathways  was  identified  as  bicistronic  in  mouse 
embryonic stem cells
 133, 160. However, separate translational start site analyses 
of ribosome profiling from 293T cells and U937 cells did not identify ECSIT as 
bicistronic (data not shown). Between these experiments, there are differences in 
both the species and the cell type analyzed. Therefore, it remains possible that 
ECSIT functions bicistronically in embryonic stem cells but not in kidney cells or 
monocytes.  Another  possibility  is  that  the  transcript  encoding  ECSIT  is  only 
bicistronic in cells derived from mice. Regardless, this indicates that the control of 
translation and start site usage is highly dynamic between species and cell types. 
Changes in translation that occur during viral infection may also drastically alter 
start  site  usage  from  host-encoded  transcripts.  Therefore  further  studies  that ! 91!
reveal  changes  in  translation  that  occur  between  cell  types  and  during  viral 
infection may reveal novel insights into the regulation of antiviral defense through 
translation. 
 
MATERIALS AND METHODS 
Cell lysis and ribosome recovery 
U937  cells  were  cultured  in  DMEM  (10%  serum)  and  were  incubated  with  or 
without 2ug/mL of harringtonine. Cyclohexamide was subsequently added at a 
concentration of 100ug/mL. Lysis buffer was added to the cells and the lysates 
were treated with RNase. Following RNA digestion, ribosomes were pelleted on 
a sucrose gradient by ultracentrifugation. 
 
Linker ligation, reverse transcription, and sequencing 
Detailed  procedures  have  been  published  previously
  135.  Briefly,  purified 
ribosome footprints were ligated to linkers for reverse transcription. This DNA can 
then  be  circularized  and  ribosomal  RNA  specific  sequences  are  depleted. 
Sequences are then amplified by PCR and barcodes can be added during this 
step to help with the analysis of sequencing results. 
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Chapter 5 
 
Conclusion 
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DISSERTATION SUMMARY 
The Bicistronic Nature of the MAVS Transcript 
  The results described in chapter two explain the mechanism responsible 
for generating the two MAVS variant proteins previously observed by western 
blot analysis. It was hypothesized that these variants, FL MAVS and miniMAVS, 
were  the  product  of  alternative  translation  initiation  at  two  unique  start  sites 
present  on  the  MAVS  transcript.  Two  start  codons  at  methionine  1  and 
methionine 142 of the annotated MAVS protein sequence were each predicted to 
generate  proteins  that  corresponded  to  the  relative  weight  of  FL  MAVS  and 
miniMAVS. Mutations to these start sites ablated the expression of the respective 
proteins both in vitro and in vivo (Figure 2.2). These genetic alterations to the 
MAVS cDNA demonstrated that two proteins were being alternatively translated 
from this single transcript, and suggested that the same mechanism occurred on 
the endogenous MAVS transcript. Ribosomal profiling was then performed to test 
whether  ribosomes  initiate  translation  from  these  two  start  codons  on  the 
endogenous transcript. In the presence of the drug harringtonine, which stalls the 
initiation step of translation, ribosomes were enriched at the sites corresponding 
to the previously identified start sites at Met1 and Met142 (Figure 2.4). These 
results lead to the conclusion that FL MAVS and miniMAVS are expressed by 
alternative translation from a single bicistronic transcript. 
  A defining feature of mRNA translation is that this process has an inherent 
directionality
  137.  Thus,  for  a  ribosome  to  initiate  protein  synthesis  from  a 
downstream start site requires a mechanism allowing it to bypass upstream start ! 94!
sites. Cis-regulatory features of the MAVS transcript were examined to better 
understand  how  the  expression  of  FL  MAVS  and  miniMAVS  is  controlled. 
Artificial start sites were introduced upstream of the miniMAVS start codon to test 
for  leaky  ribosomal  scanning.  These  start  sites  blocked  scanning  ribosomes, 
which  resulted  in  decreased  expression  of  miniMAVS.  This  indicates  that 
miniMAVS relies on leaky ribosomal scanning and that ribosomes are not directly 
recruited  by  an  IRES-like  element  (Figure  2.5).  Furthermore,  changes  in  the 
translational context of upstream start sites altered the expression of miniMAVS 
indicating  that  the  MAVS  transcript  evolved  to  permit  some  degree  of  leaky 
ribosomal scanning. In addition the presence of a naturally encoded overlapping 
uORF  positively  regulates  miniMAVS  expression  (Figure  2.6).  Based  on 
previously described examples of overlapping uORF gene regulation
 125, 143, 161, 
this suggested that some ribosomes pass the FL MAVS start site by initiating 
translation  of  a  small  uORF  peptide.  Following  uORF-mediated  start  site 
skipping, ribosomes may resume scanning and reinitiate at the miniMAVS start 
site.  Therefore,  the  endogenous  MAVS  transcript  contains  cis-regulatory 
elements, which mediate uORF start site skipping and leaky ribosomal scanning 
to ensure proper miniMAVS expression. Collectively, chapter two demonstrates 
that the MAVS transcript is bicistronic and that translation of the two variants, FL 
MAVS and miniMAVS, depend on cis-regulatory elements encoded within the 
transcript. 
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The Role of FL MAVS and miniMAVS in Antiviral Responses 
Chapter three describes the functional role of FL MAVS and miniMAVS in 
regulating the antiviral IFN and cell death responses. Using point mutations that 
eliminated  the  translational  start  codon  for  FL  MAVS  or  miniMAVS,  it  was 
demonstrated that IFN production is specifically induced by FL MAVS, whereas 
miniMAVS was incapable of inducing this antiviral response. However, when the 
two  proteins  were  expressed  in  conjunction,  the  level  of  IFN  production  was 
abrogated  as  compared  to  FL  MAVS  expression  alone  (Figure  3.2).  This 
indicated  that  miniMAVS  functioned  by  inhibiting  FL  MAVS  induced  IFN 
production. In further support of this hypothesis, IFN production and signaling 
were  completely  abrogated  when  the  expression  levels  of  miniMAVS  were 
increased relative to FL MAVS (Figure 3.2). Interestingly, when these variants 
were  expressed  either  on  their  own  or  in  conjunction,  they  were  capable  of 
inducing cell death at later time points (Figures 3.6-3.8). 
In conclusion, FL MAVS and miniMAVS can antagonize one another, and 
the strength of antiviral gene expression induced by MAVS is the result of the 
collective actions of these two MAVS variants. A competition may exist within 
cells  at  the  level  of  the  MAVS  proteins,  and  the  relative  abundance  of  each 
variant  may  determine  the  signaling  potential  of  the  RLR  pathway.  Thus,  the 
relative  level  of  miniMAVS  protein  expression  may  provide  the  host  with  the 
ability to fine tune antiviral IFN responses. While changes in the ratio of these 
two variants may control antiviral gene expression, cell death can be induced 
irrespective of their relative abundance. The ability for both variants to induce cell ! 96!
death  may  therefore  provide  a  mechanism  to  control  viral  infection  in 
environments where IFN production may be deleterious.  
 
A Search for Alternatively Translated Innate Immune Regulators 
  The  identification  of  miniMAVS  highlights  the  concept  of  immune 
regulation generated by alternative translation, and based on this example other 
antiviral  innate  immune  genes  may  also  be  regulated  in  a  similar  fashion. 
Chapter four describes a global screen to characterize the translational start sites 
utilized  in  U937  cells  by  ribosome  profiling.  Through  this  analysis,  14,336 
translation  initiation  sites  were  identified  corresponding  to  8,893  transcripts 
(Figure 4.1). This indicates that some transcripts must contain more than one 
start site and may initiate synthesis of multiple proteins similarly to the MAVS 
transcript. The bioinformatic analysis of these start sites indicate that the majority 
of the alternative start sites are uORFs. However, roughly 10% are predicted to 
generate extension or truncation variations of a canonical protein. Due to the loss 
or gain of amino acid sequence, it is likely that these variants have differential 
function compared to the canonical protein function. However, based on amino 
acid similarities with the canonical protein, these variants most likely differentially 
regulate the same biological processes the canonical proteins regulate. From the 
predicted pool of extension and truncation variants a candidate list of antiviral 
innate  immune  genes  was  generated  for  further  characterization  (Figure  4.3). 
Whether  these  variants  are  synthesized,  stable,  and  functional  remains  to  be 
determined. ! 97!
FUTURE DIRECTIONS 
miniMAVS Inhibition of FL MAVS Induced IFN Signaling 
  The results described in this dissertation indicate that miniMAVS functions 
to  inhibit  FL  MAVS  induced  IFN  production.  Preliminarily,  this  seems  to  be 
independent or downstream of FL MAVS polymerization. The fact that miniMAVS 
does  not  participate  in  polymerization  is  consistent  with  other  studies 
demonstrating  a  CARD  requirement  for  polymerization.  If  the  function  of 
miniMAVS is independent of FL MAVS polymerization, the mechanism by which 
this  inhibition  takes  place  remains  to  be  characterized.  It  is  possible  that 
miniMAVS functions to inhibit signaling by forming a complex with downstream 
signaling proteins as the interactions with TRAF2 and TRAF6 suggest. In this 
case,  downstream  signaling  proteins  may  be  part  of  an  inactive  miniMAVS 
complex and are recruited to an active FL MAVS complex for IFN signaling and 
production.  Whether  these  complexes  exist  between  endogenous  proteins  at 
steady state remains to be determined. 
  If miniMAVS is important for the control of FL MAVS signaling, then one 
would  expect  that  the  loss  of  miniMAVS  would  result  in  uncontrolled  IFN 
signaling.  However,  testing  this  hypothesis  will  prove  to  be  technically 
challenging for a few reasons. (1) Current siRNA mediated knockdown methods 
eliminate expression from an entire transcript rather than selectively from a single 
start  site.  Therefore,  a  genetically  engineered  FL  MAVS  only  construct  would 
need to be re-introduced to test for a loss of miniMAVS phenotype. However, the 
interpretation  of  results  from  an  experiment  of  this  type  may  be  complicated, ! 98!
because the transient expression of FL MAVS is known to activate the signaling 
pathway. (2) The methionine at position 142 is not conserved in mice. Therefore, 
using a mouse model to study miniMAVS function may not be an appropriate 
system. For example, the mechanisms in place that regulate the translation of FL 
MAVS and miniMAVS in humans may not be the same in mice. Alternatively, the 
mechanism by which miniMAVS inhibits FL MAVS induced IFN production may 
require other host factors not present in mice. Therefore, understanding the role 
of  miniMAVS  in  antiviral  defense  at  the  level  of  the  organism  may  not  be 
possible. 
  Due to these experimental limitations, the best approach to characterize 
the mechanism of miniMAVS inhibition will be through biochemical studies of the 
endogenously expressed human proteins. Purification and biochemical analysis 
of FL MAVS or miniMAVS can be performed over the course of antiviral signaling 
and/or  infection.  Previously  identified  post-translational  modifications  to  MAVS 
activate  or  repress  IFN  production
  97-101,  104.  Characterizing  whether  these 
modifications are specific to FL MAVS or miniMAVS and when they occur during 
the course of an infection will inform how these proteins coordinate IFN signaling. 
Furthermore, several interacting proteins positively or negatively regulate the IFN 
potential  of  MAVS
  88-91,  95,  96.  Here  again,  determining  which  interactions  are 
specific to each variant and when these interactions occur over the course of an 
infection will provide insight into how these proteins are regulating the IFN and 
cell death responses. 
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Immune Regulation Through Changes in mRNA Translation 
  Changes  in  translation  have  historically  been  associated  with  viral 
infection.  These  changes  are  the  combined  result  of  viral  manipulations  to 
subvert host translation as well as host-encoded responses (e.g. PKR) aimed to 
control viral protein synthesis
 10, 150, 158. Regardless of intent, the changes in the 
global landscape of translation during viral infection may provide a mechanism to 
regulate antiviral immune signaling. Therefore, it will be of interest to study the 
effects that this regulation has on antiviral signaling and defense mechanisms. 
While the number of publications reporting on genome-wide transcript analysis 
has exploded in the past decade, there have been relatively few genome-wide 
studies of translation
 162. However, with the advent of new technologies to study 
genome-wide  translation  its  effect  on  immune  regulation  may  soon  be  more 
clearly elucidated.  
In the context of MAVS, one might expect to observe naturally occurring 
changes in the ratio of FL MAVS to miniMAVS. For example certain cell types or 
conditions  may  require  different  IFN  responsiveness.  Changes  in  the  steady 
state  ratio  of  FL  MAVS  to  miniMAVS  may  be  one  mechanism  that  regulates 
differences in IFN production. This could be achieved through different rates of 
translation initiation or through differences in protein stability (discussed below). 
The rates of FL MAVS and miniMAVS translation initiation during viral infection or 
under other forms of stress could be determined using ribosome profiling or pulse 
chase experiments. Once a condition is identified in which translation initiation 
rates deviate from steady state expression, genetic or biochemical techniques ! 100!
could be used to identify the regulatory factors responsible. However, MAVS is 
just  one  example  of  immune  regulation  created  through  the  process  of 
translation. One benefit of the tools available to study genome-wide translation is 
the ability to identify more examples where the process of translation functions to 
regulate immune responses in an unbiased fashion. 
 
MAVS Regulation Through Changes in Protein Stability 
  As  I  alluded  to  in  the  previous  section,  the  levels  of  FL  MAVS  and 
miniMAVS could be regulated by changes to protein stability rather than changes 
in translation. Changes in FL MAVS protein stability may make a cell incapable of 
inducing IFN production in response to RNA virus infection. The converse of this 
may also be true, but because miniMAVS shares its amino acid sequence with 
FL MAVS this would require a mechanism to specifically target miniMAVS. As 
discussed  in  chapter  one,  MAVS  can  be  modified  with  ubiquitin  for  targeted 
proteasomal degradation
 97-101. In some of these studies, the ubiquitin-modified 
residue has been mapped and thus provides insight into whether FL MAVS or 
miniMAVS is targeted. However, in some cases the targeted residue is common 
between  the  two  variants.  One  way  to  determine  the  stability  of  each  variant 
would  be  to  determine  which  variants  receive  these  modifications  following 
activation of the pathway or viral infection. 
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Resolution of Innate Immune Polymers 
  The use of protein polymers for the activation of signal transduction is an 
emerging theme in the study of innate immunity. In addition to MAVS, both RIG-I 
and MDA-5 form polymers or fibrils following ligand binding
 47-49. Thus, the RLR 
pathway  seems  to  be  regulated  at  several  points  by  the  generation  of  these 
protein polymers. Additionally, this form of regulation through polymer formation 
has also been recognized in the activation of the inflammasome. Recently two 
reports  have  demonstrated  that  similarly  to  MAVS,  the  adaptor  protein  ASC 
forms prion-like polymers upon activation that are self-propagating
 163-165. Many 
of the proteins that function in these innate immune signaling pathways contain 
domains that facilitate homotypic interactions (e.g. CARD, death domain (DD), 
Pyrin  domain),  which  may  explain  why  polymer  formation  is  common  among 
them
  166.  The  ability  of  MAVS  and  ASC  to  nucleate  and  propagate  a  self-
polymerization process make these proteins prion-like, and are the first reported 
examples of prion-like polymerization having a beneficial effect in mammalian 
cells
 56, 163. This brings up the interesting question of how these polymers are 
resolved or degraded following activation. The build-up of prion aggregates is 
associated with several neurological diseases indicating that these aggregates 
are  not  easily  resolved  and  can  be  difficult  to  remove
  167.  Is  it  possible  that 
unresolved  aggregation  of  MAVS  or  ASC  manifests  in  disease?  Presumably, 
there are mechanisms in place to reset the cell back to a pre-activation state with 
the  proteins  in  their  original  conformation.  Understanding  the  regulatory ! 102!
mechanisms that control this will be of significant interest in understanding the 
maintenance of immune homeostasis. 
 
MAVS-Mediated Cell Death 
As mentioned in chapter one, MAVS mediated cell death has not been as 
clearly characterized as the MAVS dependent IFN response. The factors both 
upstream and downstream of FL MAVS and miniMAVS need to be identified and 
characterized in the context of cell death. While one may expect the upstream 
factors  to  be  common  among  IFN  signaling  and  cell  death,  several  reports 
indicate that MAVS-mediated virus-induced cell death occurs independently of 
the RLRs and IFN
 81, 85. Therefore, it remains to be determined how FL MAVS 
and  miniMAVS  sense  viral  infection  to  induce  cell  death.  Perhaps  upstream 
receptors distinct from the RLRs are uniquely responsible for this process. 
The mechanisms downstream of FL MAVS and miniMAVS that initiate cell 
death also require further elucidation, however it is worth noting that this process 
likely occurs independent of the formation of MAVS polymers. This is based on 
the  work  described  here  and  in  reports  demonstrating  the  polymerization  of 
MAVS.  miniMAVS  does  not  contain  the  required  CARD  domain  for  self-
polymerization and it does not induce FL MAVS polymerization, yet it can still 
induce  cell  death
  56,  86  (and  unpublished  observations  SW  Brubaker).  Several 
other  factors  participate  in  caspase  activation  and  MAVS-mediated  cell  death 
including VDAC1, TRADD, FADD, RIP1, and caspase 8
 53, 81, 83, 84. It remains to 
be determined whether FL MAVS and miniMAVS utilize these same mechanisms ! 103!
to induce cell death, or if there are differences in the way each variant induces 
cell death. In addition the localization requirements for cell death will also need to 
be verified. In this report and other reports on MAVS mediated cell death, it has 
been demonstrated that a proper localization domain is required for this process
 
76, 81, 86. Because this domain directs the adaptor to mitochondria, peroxisomes, 
as  well  as  MAMS  it  remains  to  be  determined  which  subcellular  location  is 
responsible  for  MAVS  mediated  cell  death.  Due  to  the  number  of  cell  death 
regulatory factors associated with mitochondria it is plausible that localization on 
this organelle may specifically be required for this phenotype. 
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CLOSING REMARKS 
  In  the  25  years  since  Charles  Janeway  Jr.  announced  his  hypothetical 
model  of  pattern  recognition,  there  has  been  an  explosion  of  research 
characterizing the complex network of innate immune response pathways. These 
innate immune responses, which are critical for containing infection and initiating 
adaptive immunity, are often characterized by dramatic changes in transcription. 
Regulating innate immune responses is not only critical for host defense, but also 
for  maintaining  immune  homeostasis.  The  work  described  here  demonstrates 
just  one  example  of  immune  regulation  that  is  controlled  by  the  process  of 
translation. However genome-wide ribosome profiling indicates that translation 
from alternative start sites, as in the case of miniMAVS, may be more prevalent 
than previously appreciated. Therefore, this dissertation not only provides insight 
into the regulation of antiviral signaling, but also provides a mandate to consider 
translation as a layer of regulation within other genes as well. 
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